NO741963L - - Google Patents
Info
- Publication number
- NO741963L NO741963L NO741963A NO741963A NO741963L NO 741963 L NO741963 L NO 741963L NO 741963 A NO741963 A NO 741963A NO 741963 A NO741963 A NO 741963A NO 741963 L NO741963 L NO 741963L
- Authority
- NO
- Norway
- Prior art keywords
- lower alkyl
- polymer
- poly
- trimethylene
- methyl
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 claims description 139
- 125000000217 alkyl group Chemical group 0.000 claims description 82
- 238000000034 method Methods 0.000 claims description 66
- -1 trimethylene- Chemical group 0.000 claims description 66
- 239000000203 mixture Substances 0.000 claims description 45
- 239000005977 Ethylene Substances 0.000 claims description 30
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 27
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 24
- 150000001450 anions Chemical class 0.000 claims description 17
- 239000000178 monomer Substances 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 14
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 12
- 235000019253 formic acid Nutrition 0.000 claims description 12
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 11
- 239000012442 inert solvent Substances 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 150000004820 halides Chemical group 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical group [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 125000001589 carboacyl group Chemical group 0.000 claims description 5
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000003843 furanosyl group Chemical group 0.000 claims description 5
- 125000003132 pyranosyl group Chemical group 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 229940072107 ascorbate Drugs 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims 5
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical group [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 96
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
- 239000000243 solution Substances 0.000 description 71
- 239000000047 product Substances 0.000 description 55
- 230000002829 reductive effect Effects 0.000 description 51
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 45
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 238000001914 filtration Methods 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 229940102396 methyl bromide Drugs 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 22
- 239000002253 acid Substances 0.000 description 20
- 230000007062 hydrolysis Effects 0.000 description 19
- 238000006460 hydrolysis reaction Methods 0.000 description 19
- 239000003456 ion exchange resin Substances 0.000 description 17
- 229920003303 ion-exchange polymer Polymers 0.000 description 17
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 15
- 239000003613 bile acid Substances 0.000 description 15
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 12
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 239000002585 base Substances 0.000 description 11
- 239000011347 resin Substances 0.000 description 11
- 229920005989 resin Polymers 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 239000011230 binding agent Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 150000003839 salts Chemical group 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 8
- 229920002873 Polyethylenimine Polymers 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000003999 initiator Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
- 239000002168 alkylating agent Substances 0.000 description 5
- 229940100198 alkylating agent Drugs 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- ZXTHWIZHGLNEPG-UHFFFAOYSA-N 2-phenyl-4,5-dihydro-1,3-oxazole Chemical compound O1CCN=C1C1=CC=CC=C1 ZXTHWIZHGLNEPG-UHFFFAOYSA-N 0.000 description 4
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000005956 quaternization reaction Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 4
- YWOIQIYQBRDOQA-UHFFFAOYSA-N 5,6-dihydro-4h-1,3-oxazine Chemical compound C1COC=NC1 YWOIQIYQBRDOQA-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000008394 flocculating agent Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000006485 reductive methylation reaction Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CEVMYGZHEJSOHZ-UHFFFAOYSA-N 1-bromo-3-methoxypropane Chemical compound COCCCBr CEVMYGZHEJSOHZ-UHFFFAOYSA-N 0.000 description 2
- GOIWZZQXWJVDOG-UHFFFAOYSA-N 2,2,2-trifluoroethyl trichloromethanesulfonate Chemical compound FC(F)(F)COS(=O)(=O)C(Cl)(Cl)Cl GOIWZZQXWJVDOG-UHFFFAOYSA-N 0.000 description 2
- VKJCJJYNVIYVQR-UHFFFAOYSA-N 2-(3-bromopropyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCBr)C(=O)C2=C1 VKJCJJYNVIYVQR-UHFFFAOYSA-N 0.000 description 2
- BJBCSGQLZQGGIQ-UHFFFAOYSA-N 2-acetamidoethyl 2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate Chemical compound C=1C=C(Cl)C=CC=1C(C(=O)OCCNC(=O)C)OC1=CC=CC(C(F)(F)F)=C1 BJBCSGQLZQGGIQ-UHFFFAOYSA-N 0.000 description 2
- GKPDXYQIQIJZJT-UHFFFAOYSA-N 2-benzyl-4,5-dihydro-1,3-oxazole Chemical compound C=1C=CC=CC=1CC1=NCCO1 GKPDXYQIQIJZJT-UHFFFAOYSA-N 0.000 description 2
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 2
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 2
- BIWJXEPRNRDVPB-UHFFFAOYSA-N 3-bromo-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCBr BIWJXEPRNRDVPB-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000002216 antistatic agent Substances 0.000 description 2
- 239000011260 aqueous acid Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 229940006460 bromide ion Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229950000958 halofenate Drugs 0.000 description 2
- 230000000260 hypercholesteremic effect Effects 0.000 description 2
- 229920000831 ionic polymer Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- ANAFTYVSHCSQPP-UHFFFAOYSA-N lithium;trimethoxyalumane Chemical compound [Li].CO[Al](OC)OC ANAFTYVSHCSQPP-UHFFFAOYSA-N 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910001507 metal halide Inorganic materials 0.000 description 2
- 150000005309 metal halides Chemical class 0.000 description 2
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- HJOOGTROABIIIU-UHFFFAOYSA-N 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine;hydrochloride Chemical compound Cl.C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 HJOOGTROABIIIU-UHFFFAOYSA-N 0.000 description 1
- GNHPNQQIVWCDEU-UHFFFAOYSA-N 1-bromo-3-methylsulfanylpropane Chemical compound CSCCCBr GNHPNQQIVWCDEU-UHFFFAOYSA-N 0.000 description 1
- DMRXISNUOWIOKV-UHFFFAOYSA-N 1-bromobutan-2-ol Chemical compound CCC(O)CBr DMRXISNUOWIOKV-UHFFFAOYSA-N 0.000 description 1
- YYTSGNJTASLUOY-UHFFFAOYSA-N 1-chloropropan-2-ol Chemical compound CC(O)CCl YYTSGNJTASLUOY-UHFFFAOYSA-N 0.000 description 1
- LDKSCZJUIURGMW-UHFFFAOYSA-N 1-isothiocyanato-3-methylsulfanylpropane Chemical group CSCCCN=C=S LDKSCZJUIURGMW-UHFFFAOYSA-N 0.000 description 1
- IDCPFAYURAQKDZ-UHFFFAOYSA-N 1-nitroguanidine Chemical compound NC(=N)N[N+]([O-])=O IDCPFAYURAQKDZ-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- DDTQLPXXNHLBAB-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetic acid Chemical compound C=1C=C(Cl)C=CC=1C(C(=O)O)OC1=CC=CC(C(F)(F)F)=C1 DDTQLPXXNHLBAB-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- VZIQXGLTRZLBEX-UHFFFAOYSA-N 2-chloro-1-propanol Chemical compound CC(Cl)CO VZIQXGLTRZLBEX-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- GUXJXWKCUUWCLX-UHFFFAOYSA-N 2-methyl-2-oxazoline Chemical compound CC1=NCCO1 GUXJXWKCUUWCLX-UHFFFAOYSA-N 0.000 description 1
- 150000000376 2-oxazolines Chemical class 0.000 description 1
- FVEZUCIZWRDMSJ-UHFFFAOYSA-N 2-propan-2-yl-4,5-dihydro-1,3-oxazole Chemical compound CC(C)C1=NCCO1 FVEZUCIZWRDMSJ-UHFFFAOYSA-N 0.000 description 1
- NNZGNZHUGJAKKT-UHFFFAOYSA-M 3-bromopropyl(trimethyl)azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCBr NNZGNZHUGJAKKT-UHFFFAOYSA-M 0.000 description 1
- HXIYCKAAQPHZBM-UHFFFAOYSA-N 3-methyl-1,2-oxazole-5-carboxylic acid Chemical compound CC=1C=C(C(O)=O)ON=1 HXIYCKAAQPHZBM-UHFFFAOYSA-N 0.000 description 1
- SQTLUXJWUCHKMT-UHFFFAOYSA-N 4-bromo-n,n-diphenylaniline Chemical compound C1=CC(Br)=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 SQTLUXJWUCHKMT-UHFFFAOYSA-N 0.000 description 1
- UFTHEDBYLPFRDP-UHFFFAOYSA-N 5,6-dihydro-2h-oxazine Chemical compound C1CC=CNO1 UFTHEDBYLPFRDP-UHFFFAOYSA-N 0.000 description 1
- WSMQKESQZFQMFW-UHFFFAOYSA-N 5-methyl-pyrazole-3-carboxylic acid Chemical compound CC1=CC(C(O)=O)=NN1 WSMQKESQZFQMFW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 241000036848 Porzana carolina Species 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- 230000003312 cholesterol blood level Effects 0.000 description 1
- 231100000739 chronic poisoning Toxicity 0.000 description 1
- 239000008395 clarifying agent Substances 0.000 description 1
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006258 conductive agent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229920001038 ethylene copolymer Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000002979 fabric softener Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 229950005493 florantyrone Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005283 haloketone group Chemical group 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229940060942 methylin Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- SDAYLWNCGSHFTH-UHFFFAOYSA-N n-(3-methylsulfanylpropyl)formamide Chemical compound CSCCCNC=O SDAYLWNCGSHFTH-UHFFFAOYSA-N 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate group Chemical group [N+](=O)([O-])[O-] NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940045681 other alkylating agent in atc Drugs 0.000 description 1
- 150000002918 oxazolines Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- MWSFALDOJIBOOK-UHFFFAOYSA-N perchloric acid;2-phenyl-4,5-dihydro-1,3-oxazole Chemical compound [O-]Cl(=O)(=O)=O.O1CC[NH+]=C1C1=CC=CC=C1 MWSFALDOJIBOOK-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- ADZWSOLPGZMUMY-UHFFFAOYSA-M silver bromide Chemical compound [Ag]Br ADZWSOLPGZMUMY-UHFFFAOYSA-M 0.000 description 1
- LFAGQMCIGQNPJG-UHFFFAOYSA-N silver cyanide Chemical compound [Ag+].N#[C-] LFAGQMCIGQNPJG-UHFFFAOYSA-N 0.000 description 1
- 229940098221 silver cyanide Drugs 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- YDTFRJLNMPSCFM-UTONKHPSSA-M sodium;(2r)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate Chemical compound [Na+].IC1=CC(C[C@@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-UTONKHPSSA-M 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical class C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VYGSFTVYZHNGBU-UHFFFAOYSA-N trichloromethanesulfonic acid Chemical class OS(=O)(=O)C(Cl)(Cl)Cl VYGSFTVYZHNGBU-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0206—Polyalkylene(poly)amines
- C08G73/0213—Preparatory process
- C08G73/0226—Quaternisation of polyalkylene(poly)amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0233—Polyamines derived from (poly)oxazolines, (poly)oxazines or having pendant acyl groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Polyesters Or Polycarbonates (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Nye ionogene polym erer New ionic polymers
Foreliggende oppfinnelse angår nye polymerer og frem-gangsmåter for deres fremstilling. Mere spesielt angår oppfinnelsen polymerer avledet fra oxazoliner og dihydro-oxaziner som har en lineær kjede fri for både forgrening og tverrbinding, og omfattende enten tertiære eller- kvartære nitrogena'tomer bundet til hverandre over ethylen- eller trimethylengrupper. The present invention relates to new polymers and methods for their production. More particularly, the invention relates to polymers derived from oxazolines and dihydro-oxazines which have a linear chain free of both branching and cross-linking, and comprising either tertiary or quaternary nitrogen atoms bonded to each other via ethylene or trimethylene groups.
Disse polymerer anvendes med fordel som antimikrobielle midler, flokkuleringsmidler, elektrisk ledende midler i papirbeiegg, antistatiske midler, cheleringsmidler og gallesyrebindende midler, såvel som i lignende anvendelser hvor deres høye ladning til vekt-forhold, og tilgjengeligheten av deres nitrogen med fordel kan anvendes . These polymers are advantageously used as antimicrobial agents, flocculants, electrically conductive agents in paper dyes, antistatic agents, chelating agents and bile acid binding agents, as well as in similar applications where their high charge to weight ratio, and the availability of their nitrogen can be advantageously used.
De er særlig nyttige som ikke-absorberbare gastrointesti- naie gallesyrebindende midler fordi, en slik binding er kjent for å redusere speilet av blodserumcholesterol. Alle tilgjengelige opp-lysninger indikerer at forekomsten av høyere enn normale blodserumcholesterolspeil i mennesker (særlig i såkalte type II Fredericksom pasienter), er forbundet med atherosclerose og andre hypercholeste-remiske sykdomstegn. Atherosclerose gir seg "til kjenne ved virk-ningene av akklusjon av sirkulasjonen, og bevirker coronare, cerebro-vaskulære og noen former av perifere vaskulære sykdommer, og er den hyppigste dødsårsak i mange land. They are particularly useful as non-absorbable gastrointestinal bile acid binding agents because such binding is known to reduce the level of blood serum cholesterol. All available information indicates that the occurrence of higher than normal blood serum cholesterol levels in humans (especially in so-called type II Fredericksom patients) is associated with atherosclerosis and other signs of hypercholesteremic disease. Atherosclerosis makes itself known by the effects of occlusion of the circulation, and causes coronary, cerebro-vascular and some forms of peripheral vascular diseases, and is the most frequent cause of death in many countries.
Ved et forsøk på å nedsette forekomsten, av atherosclerose er høye blodserumcholesterolspeil målet for forskjellige regulerings-forholdsregler, innbefattende begrensede og spesielle dieter, inhi-bering av cholesterolsynteser, aksellerert catabolisme, forhindring av gastrointestinal absorpsjon, såvel som ved hjelp av binding av gallesyrer i den gastrointestinale kanal. Den sistnevnte metode foretrekkes sterkt da den hverken krever kirurgisk inngrep eller plutselige og alvorlige forandringer i pasientenes dietvaner eller levemåte. In an attempt to reduce the incidence of atherosclerosis, high blood serum cholesterol levels are the target of various regulatory measures, including restricted and special diets, inhibition of cholesterol synthesis, accelerated catabolism, prevention of gastrointestinal absorption, as well as by binding of bile acids in the gastrointestinal tract. The latter method is strongly preferred as it requires neither surgical intervention nor sudden and serious changes in the patients' dietary habits or lifestyle.
Den nøyaktige måte ved hvilken gastrointestinal gallesyre-binding oppnår å senke blodserumcholesterolspeilet er imidlertid ukjent. Det antas at feedback mekanismer påvirker cholesterol-oxydasjonsresponser og utarmer serumcholesterol i et forsøk på å gjenopprette gallesyrespeilene. Uansett usikkerheten med hensyn til mekanismen er metoden vel akseptert.<*>Det som mangler er et bekvemt, effektivt, ikke-toksisk og lett .tolererbart bindemiddel. However, the precise mechanism by which gastrointestinal bile acid sequestration achieves lowering of the blood serum cholesterol level is unknown. It is believed that feedback mechanisms affect cholesterol oxidation responses and deplete serum cholesterol in an attempt to restore bile acid levels. Regardless of the uncertainty regarding the mechanism, the method is well accepted.<*>What is missing is a convenient, effective, non-toxic and easily tolerated binder.
Hittil har en rekke gallesyrebindende midler vært anvendt. Disse innbefatter jernsalter som danner uoppløselige felninger med gallesyrer, organiske baser som virker på lignende måte, og polymerer med salt-dannende evne. Absorberbare felleroidler representerer imidlertid akutte og kroniske forgiftningsfarer. Anvendelsen av ikke-absorberbare polymerer for å unngå slike toksiske problemer har ikke gitt et passende alternativ, fordi den gjennomsnittlige virksomme dagsdose for voksne av slike polymerer hittil anvendt er opp til 4 0 g. Det fysikalske volum av en slik dose, særlig av en vann-uoppløselig tverrbundet harpiks, kan bevirke, delvis blokkering av den gastrointestinale kanal og gir en ubehagelig, tung følelse. Videre er en ubehagelig lukt eller smak av en så stor dose vanske-lig å maskere. Until now, a number of bile acid binding agents have been used. These include iron salts that form insoluble precipitates with bile acids, organic bases that act in a similar way, and polymers with salt-forming ability. However, absorbable traps represent acute and chronic poisoning hazards. The use of non-absorbable polymers to avoid such toxic problems has not provided a suitable alternative, because the average effective daily dose for adults of such polymers used so far is up to 40 g. The physical volume of such a dose, especially of a water -insoluble cross-linked resin, can cause partial blockage of the gastrointestinal tract and gives an unpleasant, heavy feeling. Furthermore, an unpleasant smell or taste from such a large dose is difficult to mask.
Preparater av geltypen som har mindre tverrbinding, og er forgrenet, som uttrykket her er anvendt, sveller markert ved vann- sorpsjon., og skjønt de er relativt fri. for gnidningsirritasjon, bevirker de. ofte trykk.ubeh.ag. Preparations of the gel type which have less cross-linking and are branched, as the term is used here, swell markedly upon water absorption, and although they are relatively free. for rubbing irritation, they cause. often press.ubeh.ag.
Vannoppløselige polymerer som hittil har vært foreslått for anvendelse som gallesyre-bindende midler, bevirker meget høye viskositeter i oppløsningen, og har markert astringent virkning i munnhulen. Videre har de stort volum for konsumpsjon idet de opp-tar så meget som eri' ekvivalent vekt av vann i tørr form. Mere alvorlig er at de kan nedbrytes i den gastrointestinale kanal. Water-soluble polymers that have hitherto been proposed for use as bile acid-binding agents cause very high viscosities in the solution, and have marked astringent effects in the oral cavity. Furthermore, they have a large volume for consumption as they absorb as much as eri' equivalent weight of water in dry form. More seriously, they can be broken down in the gastrointestinal tract.
Følgelig har der bare vært begrenset nytte ved behandling med denne metode, skjønt forekomsten av sykdommer bundet til hyper-cholestermi er meget høy og fortsetter å stige alarmerende. Consequently, there has been only limited benefit in treatment with this method, although the incidence of diseases linked to hyper-cholestermia is very high and continues to rise alarmingly.
Flere forklaringer.har vært fremsatt på den manglende evne hos harpiksene.som hittil har vært foreslått anvendt i hyperchole-steroiemiske midler til å balansere gallesyreopptagelsen med evnen til kloridbinding. Et syn er at mindre uorganiské anioner lett kan'nå bindingsstedene. For derfor å danne en mere effektiv harpiks bør man fremskaffe en større adskillelse av bindingsstedene for volumi-nøse syrer. Et annet syn er at harpikser må være mere lipid-lignende for å penetrere in vivo de celleformasjoner som inneholder fettlignende gallesyrer, hvilket fører til forslag at nedsatt vann-oppløselighet av harpikser var ønskelig. Several explanations have been put forward for the inability of the resins which have hitherto been proposed to be used in hypercholesterolemic agents to balance bile acid absorption with the ability to bind chloride. One view is that smaller inorganic anions can easily reach the binding sites. Therefore, in order to form a more effective resin, a greater separation of the binding sites for bulky acids should be provided. Another view is that resins must be more lipid-like in order to penetrate in vivo the cell formations that contain fat-like bile acids, which leads to the suggestion that reduced water solubility of resins was desirable.
Dessverre -har disse syn ført til liten forbedring når de overføres på polymerknnstruksjon for behandling av hypercholestero-lemi. Unfortunately, these views have led to little improvement when transferred to polymer construction for the treatment of hypercholesterolemia.
Det har nu vist seg at de nye polymerer som her beskri-ves, er ualminnelig virksomme til å binde eller danne danne komplek-se med gallestyrer i den gastrointestinale kanal, og til å senke blodserumspeilene av cholesterol. It has now been shown that the new polymers described here are unusually effective in binding or forming complexes with bile ducts in the gastrointestinal tract, and in lowering blood serum levels of cholesterol.
Ved uttrykket "saltdannende nitrogen" er ment et nitrogen-atom, f.eks. en iminogruppe eller en substituert iminogruppe som er tilstrekkelig basisk til at den enten er tilstede i form av et kvartært salt eller et syreaddisjonssalt eller kan danne et med syrer. By the expression "salt-forming nitrogen" is meant a nitrogen atom, e.g. an imino group or a substituted imino group which is sufficiently basic that it is either present in the form of a quaternary salt or an acid addition salt or can form one with acids.
Uttrykket "lineær polymer hovedkjede" er anvendt for å beksrive en polymer med bare acykliske grupper, dvs. methylen eller trimethylen- eller trimethylengrupper, bundet til nitrogenatomene i en eneste kontinuerlig kjede. The term "linear polymer main chain" is used to describe a polymer with only acyclic groups, ie methylene or trimethylene or trimethylene groups, attached to the nitrogen atoms in a single continuous chain.
Uttrykket " uforgrenet" er anvendt for å betegne en poly-radr som ikke har noen gjentatte monomerenheter som rager ut fra den polymere, hovedkjede, og uttrykket "tverrbundet" er anvendt på vanlig måte for å betegne, en forbindelse mellom to hovedkjeder. The term "unbranched" is used to denote a poly-radr which has no repeating monomer units protruding from the polymeric backbone, and the term "cross-linked" is commonly used to denote a connection between two backbones.
At polymerene ifølge oppfinnelsen er lineære og uforgrenet er av den største viktighet for forståelsen av fremskrittene ved foreliggende oppfinnelse. Mens således noen publikasjoner, f.eks. US patent 3 30.8 020 angår monomerenheter som ligner monomerenhetene ved foreliggende oppfinnelse, må det huskes at disse tidligere kjente polymerer, på grunn av materialene og fremgangsmåtene som anvendes til å fremstille dem, er sterkt forgrenet. Videre har, såvidt vites, Gibbs et al, Journal of American Chemical Society, 57_ (1137 That the polymers according to the invention are linear and unbranched is of the greatest importance for the understanding of the advances in the present invention. While thus some publications, e.g. US patent 3 30.8 020 relates to monomer units similar to the monomer units of the present invention, it must be remembered that these previously known polymers, due to the materials and methods used to prepare them, are highly branched. Furthermore, as far as is known, Gibbs et al, Journal of American Chemical Society, 57_ (1137
(1935) og Noguchi et al, Macromolecules, 5_, 261 (1972) rett når de hevder at forsøk på å polymerisere dimethylaminoethylenhalogenider gir bare sykliske dimerer, til trots for anførslene i tyske patenter 1 131 694 og 1 126 396. (1935) and Noguchi et al, Macromolecules, 5_, 261 (1972) are correct when they claim that attempts to polymerize dimethylaminoethylene halides give only cyclic dimers, despite the statements in German patents 1,131,694 and 1,126,396.
Polymerene ifølge oppfinnelsen har den generelle formel: The polymers according to the invention have the general formula:
hvor -og F^/som er like eller forskjellige, er hydrogen; laverealkyl; monohydroxy-substituert C-^til C4alkyl, polyhydroxy-substituert C3til Cg alkyl eller polyhydroxysubstituert C^til Cg cycloalkyl; C3til Cjcycloalkyl; C3til C7cycloalkyl-substituert lavere alkyl^lavere alkyl-substituert C3til C7 cycloalkyl; ammoniolavere alkyl; lavere alkylammon^olavere-alkyl; dilavere-alkylammoniolavere-alkyl; trilavere alkylammonia lavere alkyl; carboxylavere alkyl; carbolaverealkoxylaverealkyl; C3til Cjalkenyl; C3ti - C-y alkynyl; aralkyl, f. eks. 2-(1-nafthyl)-ethyl, benzyl; carbamyllaverealkyl; f luorlaverealkyl, f .eks. co-trifluorlaverealkyl; cyanolaverealkyl; guanidinolaverealkyl; carbamidinolaverealkyl; N-laverealkylcarbamidonolaverealkyl; laveraalkoxylavere-alkyl; laverealkylthiolaverealkyl; furanosyl; pyranosyl, f. eks. ot-B-glucopyranosyl; eller laverealkanoyllaverealkyl. where -and F^/which are the same or different, are hydrogen; lower alkyl; monohydroxy substituted C 1 to C 4 alkyl, polyhydroxy substituted C 3 to C 8 alkyl or polyhydroxy substituted C 1 to C 8 cycloalkyl; C 3 to C 1 cycloalkyl; C3 to C7 cycloalkyl-substituted lower alkyl; lower alkyl-substituted C3 to C7 cycloalkyl; ammonium lower alkyl; lower alkylammonia lower alkyl; dilave-alkylammoniolave-alkyl; trilower alkylammonia lower alkyl; carboxyl lower alkyl; carbolaverealkylloweralkyl; C3 to C1alkenyl; C31 - C-y alkynyl; aralkyl, e.g. 2-(1-naphthyl)-ethyl, benzyl; carbamyl lower alkyl; fluorine lower alkyl, e.g. c -trifluorolower alkyl; cyano lower alkyl; guanidinolower alkyl; carbamidinolaverealkyl; N-lower alkylcarbamidon lower alkyl; lower aralkyl lower alkyl; lower alkylthio lower alkyl; furanosyl; pyranosyl, e.g. ot-B-glucopyranosyl; or lower alkanoyl lower alkyl.
R 3 og , som er like eller forskjellige, er laverealkyl; monohydroxy-substituert C-j_ til C^alkyl, polyhydroxy-substituert C3 til Cg alkyl eller polyhydroxy-substituert C^til Cg cycloalkyl; C-j til C7cycloalkyl; C3til C-, cycloalkyl-subs.tituert laverealkyl; laverealkyl-subatituert C^til C-, cycloalkyl; ammoniolaverealkyl;" laverealkylammoniolaverealkyl; dilaverealkylammoniolaverealkyl> trilaverealkylammoniolaverealkyl; carboxylaverealkyl; carbolaverealkoxylaverealkyl; C3til C-, alkenyl; C3til C- j alkynyl; aralkyl, f.eks. 2-(1-naf thyl). -ethyl, benzyl; carbamyllaverealkyl; fluorlaverealkyl, f.eks. w-trifluorlaverealkyl; cyanolaverealkyl; guanidinolaverealkyl; carbamidonolaverealkyl; N-laverealkyl-carbamidinolaverealkyl; laverealkoxylaverealkyl;.' laverealkylthiolaverealkyl; furanosyl; pyranosyl, f.eks. a-j}-gluco^pyranosyl; eller laverealkanoyllaverealkyl. R 3 and , which are the same or different, are lower alkyl; monohydroxy substituted C 1 to C 8 alkyl, polyhydroxy substituted C 3 to C 8 alkyl or polyhydroxy substituted C 1 to C 8 cycloalkyl; C 1 to C 7 cycloalkyl; C3 to C-, cycloalkyl-substituted lower alkyl; lower alkyl-substituted C 1 to C-, cycloalkyl; ammoniolaverealkyl;" loweralkylammoniolaverealkyl; dilaverealkylammoniolaverealkyl> trilaverealkylammoniolaverealkyl; carboxylaverealkyl; carbolaverealoxylaverealkyl; C3 to C-, alkenyl; C3 to C- j alkynyl; aralkyl, e.g. 2-(1-naphthyl). -ethyl, benzyl; carbamyllaverealkyl; fluorolaverealkyl, f .eg w-trifluorolower alkyl; cyano lower alkyl; guanidino lower alkyl; carbamidon lower alkyl; N-lower alkyl-carbamidin lower alkyl; lower alkoxy lower alkyl;.' lower alkylthiolower alkyl; furanosyl; pyranosyl, eg α-j}-gluco^pyranosyl; or lower alkanoyl lower alkyl.
n er et helt tall slik at vektgjennomsnitts molekylvekten er fra 300til50000j n is an integer so that the weight average molecular weight is from 300 to 50000j
m er 0 eller•1; m is 0 or•1;
Z er et énverdig eller flerverdig motanion; Z is a monovalent or polyvalent counteranion;
Q er ethylen eller trimethylen, og Q is ethylene or trimethylene, and
symbolet betegner en oinding til flere av gruppene the symbol denotes an entry to several of the groups
hvor Q, Z, m, R-^, R2 / Rj-°9R 4 er som ovenfor angitt. T-^ og T2er endegrupper på polymeren og er where Q, Z, m, R-^, R2 / Rj-°9R 4 are as indicated above. T-^ and T2 are end groups on the polymer and are
eller et dihydro-1,3-oxaz'lnium- eller et A -oxazolinium-kompleks med et anion av initiatoren hvor £3/Z, m og Q er som ovenfor angitt, R5er valgt fra den samme gruppe som R-^og , men kan være den samme eller forskjellig fra én eller begge av R-^og R3, og R er et fragment avledet av et oppløsningsmiddel hvori ring-åpningen ble utført, f.eks. hydrogen hvis en vandig behandling ble anvendt, eller et alkyl hvis en alkoholisk behandling ble anvendt. or a dihydro-1,3-oxazolinium or an A-oxazolinium complex with an anion of the initiator where £3/Z, m and Q are as above, R5 is selected from the same group as R-^ and , but may be the same or different from one or both of R 1 and R 3 , and R is a fragment derived from a solvent in which the ring opening was performed, e.g. hydrogen if an aqueous treatment was used, or an alkyl if an alcoholic treatment was used.
Den nøyaktige natur av identiteten av T er i virkeligheten uten betydning for oppfinnelsen, eller anvendbarheten av de heretter beskrevne polymerer. The precise nature of the identity of T is really immaterial to the invention, or the utility of the polymers described hereafter.
Betegnelsen "lavere" er her anvendt for å betegne fra 1 til 4 carbonatomer, og kan, som de ovenfor omtalte alkylgrupper, være en rett kjede. The term "lower" is used here to denote from 1 to 4 carbon atoms, and can, like the above-mentioned alkyl groups, be a straight chain.
Hvis i det ovenstående m er 1, Q er trimethylen og R^, R2 r R3og R^er lavere alkyl, er de således beskrevne forbindelser kjente. Allikevel er de her angitte metoder for å fremstille disse forbindelser nye. If in the above m is 1, Q is trimethylene and R 1 , R 2 , R 3 and R 1 are lower alkyl, the compounds thus described are known. Nevertheless, the methods indicated here for preparing these compounds are new.
Ved en foretrukket utførelsesform har polymeren strukturen angitt ved følgende formel: hvor betegner en bidning til én eller flere grupper In a preferred embodiment, the polymer has the structure indicated by the following formula: where denotes a bond to one or more groups
Z, T-^, Qim og n er som ovenfor angitt. Z, T-^, Qim and n are as indicated above.
Ved en annen foretrukken utførelsesform har polymeren-strukturen angitt ved følgende formel: hvor betegner strukturen angitt ved én eller flere grupper: In another preferred embodiment, the polymer has the structure indicated by the following formula: where denotes the structure indicated by one or more groups:
Z ,, T2.'<T>2'®'m°9n er sora ovenfor angitt. Z ,, T2.'<T>2'®'m°9n is sora indicated above.
I denne beskrivelse betegner Z et anion som motvirker ;• ladningen på den kvartære eller protonerte iminogruppe, og kan således være et&nverdig anion. Det vil imidlertid forståes at Z også kan innbefatte flerverdige anioner hvor et anion kan motvirke ladningen på mere enn ;én ladet iminogruppe. Z kan således innbefatte anioner av uorganiske syrer såvel som fra organiske syrer som f..eks. halogenid, f.eks. klorid, bromid eller jodid; sulfat; bisulfat; fosfat; acetat; ascorbat; citrat; hydroxycitrat; carbonat; bicarbD-nat; nicotinat; glycinat; taurinat; salicylat; og andre anioner avledet av fysiologisk ikke-giftige syrer, særlig salter av fysiologisk aktive syrer som dem som .avledes av clofibrat og halofenat, In this description, Z denotes an anion which counteracts the charge on the quaternary or protonated imino group, and can thus be an ethene-valent anion. However, it will be understood that Z can also include multivalent anions where an anion can counteract the charge on more than one charged imino group. Z can thus include anions from inorganic acids as well as from organic acids such as e.g. halide, e.g. chloride, bromide or iodide; sulfate; bisulfate; phosphate; acetate; ascorbate; citrate; hydroxycitrate; carbonate; bicarbD-nate; nicotinate; glycinate; taurinate; salicylate; and other anions derived from physiologically non-toxic acids, particularly salts of physiologically active acids such as those derived from clofibrate and halofenate,
dvs. 2-(p-klorfenoxy)-2-methylpropionsyre og 3-trifluormethylfenoxy-(4-klorfenyl)-eddiksyre. Når slike anioner av fysiologisk aktive forbindelser anvendes til å nøytralisere kvartære eller protonerte iminogrupper, er det'åpenbart at bare en del av de ladede dmino-grupper kan nøytraliseres på denne måte. Mengden av anion fra den fysiologisk aktive forbindelse • avpasses i et slikt forhold at mengden som administreres med polymerdosen, kan falle innen det ønskede område for den fysiologisk aktive forbindelse. i.e. 2-(p-chlorophenoxy)-2-methylpropionic acid and 3-trifluoromethylphenoxy-(4-chlorophenyl)-acetic acid. When such anions of physiologically active compounds are used to neutralize quaternary or protonated imino groups, it is obvious that only a part of the charged dmino groups can be neutralized in this way. The amount of anion from the physiologically active compound • is adjusted in such a ratio that the amount administered with the polymer dose can fall within the desired range for the physiologically active compound.
Polymerene ifølge oppfinnelsen fåes ved en rekke trinn hvorav det første er polymerisasjonen av et A 2-oxazolin med formelen : et 5,6-dihydro-4H-l,3-oxazin med formelen: The polymers according to the invention are obtained by a series of steps, the first of which is the polymerization of an A 2-oxazoline with the formula: a 5,6-dihydro-4H-1,3-oxazine with the formula:
t t
hvor R' er hydrogen, laverealkyl, fenyl, nafthyl eller nafthylmethyl. where R' is hydrogen, lower alkyl, phenyl, naphthyl or naphthylmethyl.
Fortrinnsvis er R' hydrogen. Preferably R' is hydrogen.
Trinn T - Polymer isas jon. Stage T - Polymer isation.
Polymerisasjanen ,ay. 2-R'.-A. 2-oxazolinene er kjent og beskrevet i. Polymer Journal, 3y 35 (19.72). Det har imidlertid vist seg at en mere pålitelig polymerisasjon fåes ved å anvende trifluormethylsulfonsyre i stedet for initiatorene angitt i litteraturen. The polymerization, ay. 2-R'.-A. The 2-oxazolines are known and described in. Polymer Journal, 3y 35 (19.72). However, it has been shown that a more reliable polymerization is obtained by using trifluoromethylsulfonic acid instead of the initiators indicated in the literature.
I alminnelighet anvendes fra 0,.005 til 0,1 mol trifluormethylsulfonsyre for Kvert mol av et 2-R<1->A<2>~oxazolin, idet 0,01 mol trifluormethylsulfonsyre pr. mol 2-R'-A 2-oxazolin foretrekkes. In general, from 0.005 to 0.1 mol of trifluoromethylsulfonic acid is used for each mole of a 2-R<1->A<2>~oxazoline, with 0.01 mol of trifluoromethylsulfonic acid per mol 2-R'-A 2-oxazoline is preferred.
Polymerisasjonen av 2-R'-5,6-dihydro-4H-l,3-oxazinet er også kjent, og omtalt i Macromolecules, 6_, 495 (1973). Den foretrukne initiator blandt de kjente initiatorer er methyljodid. The polymerization of 2-R'-5,6-dihydro-4H-1,3-oxazine is also known, and discussed in Macromolecules, 6_, 495 (1973). The preferred initiator among the known initiators is methyl iodide.
I alminnelighet utføres polymerisasjonen av 2-R'-A 2-exa-zolinene og 2-R'-5,6-dihydro-4H-l,4-oxazinene i et'lukket system i et inert oppløsningsmiddel og under en inert atmosfære som nitrogen, ved et trykk på 1 - 100 atm og oppvarming til fra 30° C til 120° C i 1-12 timer. Ved inert oppløsningsmiddel menes her og ellers i beskrivelsen, et oppløsningsmiddel som ikke er reaktivt underdidisse betingelser.hverken emed reaktanter, produkter eller i seg selv, idet dimethylformamid erher er det foretrukne 'oppløsningsmiddel. In general, the polymerization of the 2-R'-A 2-exa-zolines and 2-R'-5,6-dihydro-4H-1,4-oxazines is carried out in a closed system in an inert solvent and under an inert atmosphere which nitrogen, at a pressure of 1 - 100 atm and heating to from 30° C to 120° C for 1-12 hours. By inert solvent is meant here and elsewhere in the description, a solvent which is not reactive under these conditions, either with reactants, products or in itself, dimethylformamide being the preferred solvent here.
Når reaksjonen kanses for'å være fullstendig, bestemt ved forsvinningen av -C=N-dobbelbindingen, blir polymerisasjonsreaksjons-blahdingen, som nu omfatter polymeren: hvor R<1>, Q og n er som ovenfor angitt, og T, er When the reaction is deemed to be complete, as determined by the disappearance of the -C=N double bond, the polymerization reaction mixture, which now comprises the polymer, becomes: where R<1>, Q and n are as above, and T, is
hvor Y er et anion fra initiatoren, A er hydrogen eller et initia-torfragment som methyl fra methyljodid, og Q og R som ovenfor angitt, behandlet med et vannfri.tt oppløsningsmiddel fortrinnsvis en alkohol eller ether som methanol eller ethylether. Etter filtrering og vask- where Y is an anion from the initiator, A is hydrogen or an initiator fragment such as methyl from methyl iodide, and Q and R as indicated above, treated with an anhydrous solvent, preferably an alcohol or ether such as methanol or ethyl ether. After filtering and washing
ing med vannfritt oppløsningsmiddel oppsamles polymeren og tørkes. ing with anhydrous solvent, the polymer is collected and dried.
Etter isolering underkastes polymeren deretter et av tre alternative, trinn to: hydrolyse, direkte reduksjon eller reduserende 'methylering. After isolation, the polymer is then subjected to one of three alternative, step two: hydrolysis, direct reduction, or reductive methylation.
Trinn 2A Hydrolyse Step 2A Hydrolysis
Hydrolysen som spalter av acylgruppen utføres ved å.omsette polymeren VI med en vandig syre som vandig mineralsyre, f.eks. saltsyre, eller en base som alkalihydroxyd hvilket gir polymeren: The hydrolysis which cleaves the acyl group is carried out by reacting the polymer VI with an aqueous acid such as aqueous mineral acid, e.g. hydrochloric acid, or a base such as alkali hydroxide which gives the polymer:
hvor A, m, Q, Z, R og n er som ovenfor angitt, og Z er fortrinnsvis et halogenid. where A, m, Q, Z, R and n are as above, and Z is preferably a halide.
Den alkaliske hydrolyse utføres ved å blande polymeren med en vandig oppløsning av fra mettet til 0,IN base, pssende alkalihydroxyd, og fortrinnsvis natriumhydroxyd. Syrehydrolysen utføres i en 1 - 2 N vandig mineralsyre, f.eks. saltsyre eller svovelsyre. The alkaline hydrolysis is carried out by mixing the polymer with an aqueous solution of saturated to 0.1N base, alkaline hydroxide, and preferably sodium hydroxide. The acid hydrolysis is carried out in a 1 - 2 N aqueous mineral acid, e.g. hydrochloric or sulfuric acid.
Hydrolysen utføres under omrøring og oppvarming i minst The hydrolysis is carried out with stirring and heating for at least
3 til 30 timer. Fortrinnsvis, for.å oppnå"i det vesentlige fullstendig hydrolyse og: et svakt offer i molekyl-vekten, kan hydrolysen utføres i et lukket kar ved en temperatur fra 40° C til 180° C. Mengden av vandig hydrolyseringsoppløsning er ikke kritisk, forutsatt at omrøringen er god og at minst to ganger den teoretiske mengde alkali eller'.syre anvendes 'til å' bevirke hydrolysen. 3 to 30 hours. Preferably, in order to obtain substantially complete hydrolysis and: a slight sacrifice in molecular weight, the hydrolysis may be carried out in a closed vessel at a temperature of from 40° C. to 180° C. The amount of aqueous hydrolyzing solution is not critical, provided that the stirring is good and that at least twice the theoretical amount of alkali or acid is used to effect the hydrolysis.
Fra basehydrolysen fåes polymeren VII hvor m er 0, og syrehydrolysen eller påfølgende syring av den basehydrolyserte polymer gir polymeren VII hvor m er 1. From the base hydrolysis, the polymer VII is obtained where m is 0, and the acid hydrolysis or subsequent acidification of the base hydrolysed polymer gives the polymer VII where m is 1.
Trinn 2B - direkte reduksjon Step 2B - direct reduction
Polymer VI reduseres direkte til polymer VIII ved reduksjon av acylgruppen. Polymer VI is reduced directly to polymer VIII by reduction of the acyl group.
hvor A, Z, Q, R<1>, R , Z, m og n er som ovenfor angitt. where A, Z, Q, R<1>, R , Z, m and n are as indicated above.
Fortrinnsvis oppløses polymeren i et inert oppløsningsmid-del og blandes langsomt med minst én molekvivalent av et kjemisk reduksjonsmiddel som diboran, som også er oppløst i et inert oppløs-ningsmiddel. De foretrukne oppløsningsmidler er tetrahydrofuran og blandinger derav med ethylenglycoldimethylether. Etter tilsetningen kokes reaksjonsblandingen under tilbakeløp i 1 - 12 timer, avkjøles og syres. Andre reduksjonsmidler som kan anvendes i stedet for diboranet, innbefatter aluminiumhydrid, lithiumaluminiumhydrid cg lithiumtrimethoxyaluminiumhydrid. Preferably, the polymer is dissolved in an inert solvent and mixed slowly with at least one molar equivalent of a chemical reducing agent such as diborane, which is also dissolved in an inert solvent. The preferred solvents are tetrahydrofuran and mixtures thereof with ethylene glycol dimethyl ether. After the addition, the reaction mixture is boiled under reflux for 1 - 12 hours, cooled and acidified. Other reducing agents which can be used in place of the diborane include aluminum hydride, lithium aluminum hydride and lithium trimethoxy aluminum hydride.
Alternativt overføres amidgruppene av polymer VI ved alkylering til iminoestere med triethyloxonium-tetrafluorboratkompleks i methylenklorid ved 2 5° C. Iminoesterenhetene reduseres så lett til tertiære aminenheter som med natriumborhydrid i ethanol ved 0°Ci_ til 25° C. Alternatively, the amide groups of polymer VI are transferred by alkylation to iminoesters with triethyloxonium-tetrafluoroborate complex in methylene chloride at 25°C. The iminoester units are reduced to tertiary amine units as easily as with sodium borohydride in ethanol at 0°Ci_ to 25°C.
Trinn- 2C - Reduserende methylering Step- 2C - Reductive methylation
Ved denne metode oppvarmes polymeren VI hvor R' er hydrogen, med en blanding av mere enn. én ekvivalent av hver av formaide-hyd og maursyre, og behandles så med en vandig syre- og inndampes til tørrhet under nedsatt trykk for å få polymeren: In this method, the polymer VI where R' is hydrogen is heated with a mixture of more than. one equivalent each of formamide and formic acid, and then treated with an aqueous acid and evaporated to dryness under reduced pressure to give the polymer:
hvor Rg, Q, Z, R' , m og n er som (Ovenf or angxtt. where Rg, Q, Z, R', m and n are as (Above angxtt.
Polymeren som skal underkastes reduserende methylering tilsettes til en blanding av 97 -' 100 %-i.g maursyre, "dg fortrinnsvis 38 %-i.g vandig formaldehyd, og reaksjonsblandingen oppvarmes ved The polymer to be subjected to reductive methylation is added to a mixture of 97-100%-g formic acid, preferably 38%-g aqueous formaldehyde, and the reaction mixture is heated at
30 - 100° C- i 20 - 100 timer. Skjønt høyere reaksjonstemperaturer 30 - 100° C- for 20 - 100 hours. Although higher reaction temperatures
ikke er utelukket, gjør den økede hastighet av termisk spaltning av maursyre, og risikoen for nedbrytning av polymeren, bruken av høyere temperaturer mindre tiltrekkende. Blandingen behandles så med en vandig mineralsyre, fortrinnsvis saltsyre, og overskuddet av maursyre, formaldehyd og mineralsyre fjernes ved inndampning under nedsatt trykk. is not excluded, the increased rate of thermal decomposition of formic acid, and the risk of degradation of the polymer, make the use of higher temperatures less attractive. The mixture is then treated with an aqueous mineral acid, preferably hydrochloric acid, and the excess of formic acid, formaldehyde and mineral acid is removed by evaporation under reduced pressure.
Trinn 3 - Direkte methylering Step 3 - Direct methylation
Polymer VII hvor m er 0, methyleres direkte ved å oppvarme polymeren i en blanding av mer enn én ekvivalent av hver av formaldehyd og maursyre under betingelser angitt i trinn 2C, for å få polymer IX, hvor R5, Q, Z, R—, m og n er som ovenfor angitt. Polymer VII where m is 0 is directly methylated by heating the polymer in a mixture of more than one equivalent each of formaldehyde and formic acid under conditions set forth in step 2C to give polymer IX where R 5 , Q, Z, R—, m and n are as stated above.
Trinn 4 - Addisjon av R^og R^ til polymer VII Step 4 - Addition of R^ and R^ to Polymer VII
For polymerer med formel X hvor R3og R4er like, behandles, polymer VII hvor m er 0, med et overskudd varierende fra 1,5-8 ekvivalenter, og fortrinnsvis 4 ekvivalenter, av et alkyleringsmid-del RX i et inert oppløsningsmiddel ved temperaturer fra 30 tii 100° C. Reaksjonen utføres ved å oppløse polymeren i et inert. opp-løsningsmiddel som"alkoholer, ketoner eller dimethylformamid. Foretrukne oppløsningsmidler innbefatter methanol, aceton og dimethylformamid, og foretrukne temperaturer er mellom 50° C og 75° C. For polymers of formula X where R3 and R4 are equal, polymer VII where m is 0 is treated with an excess varying from 1.5-8 equivalents, and preferably 4 equivalents, of an alkylating agent RX in an inert solvent at temperatures from 30 tii 100° C. The reaction is carried out by dissolving the polymer in an inert. solvent such as alcohols, ketones or dimethylformamide. Preferred solvents include methanol, acetone and dimethylformamide, and preferred temperatures are between 50°C and 75°C.
Dette resulterer i en polymer med formel X hvor A, Q, Z, RX og n er som ovenfor angitt, og m er 1, og Z~ er X . Behandling av polymer X med nøyaktig en ekvivalent base gir polymer X hvor m er 0. This results in a polymer of formula X where A, Q, Z, RX and n are as above, and m is 1, and Z~ is X . Treatment of polymer X with exactly one equivalent base yields polymer X where m is 0.
For polymerer med formel X hvor R3og R4 er forskjellige, behandles polymer VII hvor m er 0, med mindre enn en ekvivalent mengde av et alkyieringsmiddel R3X og derpå etter nøytralisasjon med en tilsvarende ekvivalent base, behandles mellomproduktet med tilstrekkelig R^X til fullstendig alkylering. Begge reaksjoner ut-føres i et inert oppløsningsmiddel ved temperaturer fra 30° C til 100° C. Reaksjonene utføres ved å oppløse polymeren i et inert oppløsningsmiddel som alkoholer, ketoner eller dimethylf ormamid Foretrukne oppløsningsmidler innbefatter methanol, aceton og dimethylformamid, og. foretrukne temperaturer er mellom 50° C og For polymers of formula X where R 3 and R 4 are different, polymer VII where m is 0 is treated with less than an equivalent amount of an alkylating agent R 3 X and then, after neutralization with a corresponding equivalent base, the intermediate is treated with sufficient R 3 X for complete alkylation. Both reactions are carried out in an inert solvent at temperatures from 30° C to 100° C. The reactions are carried out by dissolving the polymer in an inert solvent such as alcohols, ketones or dimethylformamide. Preferred solvents include methanol, acetone and dimethylformamide, and. preferred temperatures are between 50° C and
7 5, o C. Syrenøytralisas.jnn gir polymer X hvor A, Q, Z, R x og n er som ovenfor angitt, og.m er 1, og Z. er X .. Behandling av polymer X med'nøyaktig en ekvivalent base gir. polymer X hvor m er 0. 7 5, o C. Acid neutralization gives polymer X where A, Q, Z, R x and n are as above, and m is 1, and Z is X .. Treatment of polymer X with exactly one equivalent base provides. polymer X where m is 0.
Trinn 5 - Kvarternisering - Addisjon av R-^, Step 5 - Quaternization - Addition of R-^,
Polymer VIII fra trinn 2B, polymer IX fra trinn 2C eller trinn 3, eller polymer X fra trinn 4, i alminnelighet erholdt som deres syreaddisjonssalter (m = 1), overføres til den frie baseform (m = 0) ved behandling med en ekvivalent mengde base. På dette trinn er det bskvemt, skjønt ikke nødvendig, å fjerne eventuelle uorganiske salter ved ultrafiltreringsmetoder. Dette har den ytterligere fordel også å eliminere eventuelt andre uønskede lavmoleky-lære stoffer.- Den vandige oppløsning av polymeren inndampes så under nedsatt trykk og produktet tørkes før kvaterniseringsreaksjonen som fører til polymerer med formel I. Kvaterniseringsreaksjonen utføres i et inert oppløsningsmiddel som en alkohol, keton eller dimethylformamid. Methanol, aceton og dimethylformamid er foretrukne oppløsningsmidler. Kvateriseringsmidlene er vanligvis halogenid-holdige forbindelser, fortrinnsvis gromforbindelser; men andre alkyleringsmidler som.toluensulfonatestere eller triklormethylsulfonat-estere kan også anvendes. Når R-^ og R2er like, anvendes et rimelig overskudd av alkyleringsmidlet RX; og når R-^og R2er forskjellige, behandles polymeren først med en begrenset mengde (5 - 95 % av dat ekvivalente) av R-^X. Etter at reaksjonen er fullstendig, behandles produktet med et overskudd av reagenset R2X- Når alkyleringsreak-tivitetene for reagensene R-^X og R2X er like, kan reaksjonen utføres i en blanding av R-^X og R2X i et enkelt trinn. R^X og R2X kan være enkle alkylhalogenider og kan også ha andre funksjonelle grupper som ikke griper forstyrrende inn i kvarteriseringsreaksjonen. En enkel, men på ingen måte uttøjnmende liste av godtagbare kvarteriserings-reagenser innbefatter halogenalkylsyreestere, halogenalkylsyreami-der, halogenketoner, fluoralkyltriklormethylsulfonater, alkylhalo- genhydrlner , aralkylhalogeni.der, ammoni.ualky lhalo<g>enider, lavere alkyl-^substituerte ammoni.oalk.ylhalogenider, alkoxyalkylhalogenider, alkylthi.oalkylhalogenider, allylhalogenider og propargylbromid. Polymer VIII from step 2B, polymer IX from step 2C or step 3, or polymer X from step 4, generally obtained as their acid addition salts (m = 1), is converted to the free base form (m = 0) by treatment with an equivalent amount base. At this stage it is convenient, although not necessary, to remove any inorganic salts by ultrafiltration methods. This has the further advantage of also eliminating any other unwanted low-molecular substances. - The aqueous solution of the polymer is then evaporated under reduced pressure and the product is dried before the quaternization reaction that leads to polymers of formula I. The quaternization reaction is carried out in an inert solvent such as an alcohol, ketone or dimethylformamide. Methanol, acetone and dimethylformamide are preferred solvents. The quaternizing agents are usually halide-containing compounds, preferably grom compounds; but other alkylating agents such as toluenesulfonate esters or trichloromethylsulfonate esters can also be used. When R 1 and R 2 are equal, a reasonable excess of the alkylating agent RX is used; and when R₂ and R₂ are different, the polymer is first treated with a limited amount (5-95% of dat equivalent) of R₂X. After the reaction is complete, the product is treated with an excess of the reagent R2X- When the alkylation reactivities of the reagents R2X and R2X are equal, the reaction can be carried out in a mixture of R2X and R2X in a single step. R₂X and R₂X can be simple alkyl halides and can also have other functional groups that do not intervene disturbingly in the quartering reaction. A simple but by no means exhaustive list of acceptable quaternization reagents includes haloalkyl acid esters, haloalkyl acid amides, haloketones, fluoroalkyltrichloromethylsulfonates, alkylhalohydrins, aralkyl halides, ammonium alkyl halo<genides, lower alkyl-substituted ammonioalcs .yl halides, alkoxyalkyl halides, alkylthioalkyl halides, allyl halides and propargyl bromide.
Reaksjonen utføres vanligvis ved å oppvarme en oppløsning av polymeren og alkyleringsmidlet i. methanol, aceton eller dimethylformamid ved 35° C - 10.0° C i. 3 - 16 timer. Med særlig reaktive alkyleringsmidler anvendes, en reaksjonstemperatur på 50° C. Produktet isoleres, vanligvis direkte ved filtrering., men i noen tilfeller er det nødvendig å fortynne reaksjonsblandingen med flere volum ether før filtrering. Produktet tørkes vanligvis delvis, males til et pulver og tørkes så under nedsatt trykk ved temperaturer fra 25° C til 60° C. The reaction is usually carried out by heating a solution of the polymer and the alkylating agent in methanol, acetone or dimethylformamide at 35° C - 10.0° C for 3 - 16 hours. With particularly reactive alkylating agents, a reaction temperature of 50° C is used. The product is isolated, usually directly by filtration, but in some cases it is necessary to dilute the reaction mixture with several volumes of ether before filtration. The product is usually partially dried, ground to a powder and then dried under reduced pressure at temperatures from 25°C to 60°C.
Trinn 6 - Ionebytter Step 6 - Ion Exchange
Anionene av polymer I er i alminnelighet begrenset til halogenid ved metodene i de foregående trinn. Det fulle område av •polymerer hvor anionet Z~ er forskjellig fra halogenid, kan fåes ved å oppløse polymer I med et halogenidanion i .vann, alkohol eller blandinger derav, i et hvilket som helst forhold og føre oppløsnin-gen gjennom et lag av anionbytteharpiks, enten en syntetisk eller en zeolittype, .hvor halogenidionet utbyttes og erstattes med Z~. Anionbyttemetcden unccr anvendelse av en harpiksmetode kan være direkte, dvs. utbytning av halogenidionet med Z , eller man kan først utbytte halogenidionet med OH~, og derpå enten ved en påføl-gende ionebytting eller enkel nøytralisasjon utbytte OH~ med Z . The anions of polymer I are generally limited to halide by the methods in the preceding steps. The full range of polymers where the anion Z~ is different from halide can be obtained by dissolving polymer I with a halide anion in water, alcohol or mixtures thereof, in any ratio and passing the solution through a layer of anion exchange resin , either a synthetic or a zeolite type, where the halide ion is exchanged and replaced by Z~. The anion exchange method without the use of a resin method can be direct, i.e. replacement of the halide ion with Z , or one can first replace the halide ion with OH~, and then either by a subsequent ion exchange or simple neutralization replace OH~ with Z .
Dessuten kan kjemiske utbytningmetoder anvendes når et metall av et metallhalogenid er mindre oppløselig enn det tilsatte metallsalt MZ. -Det utfelte metallhalogenid kan så filtreres fra den oppløselige polymer I. Moreover, chemical recovery methods can be used when a metal of a metal halide is less soluble than the added metal salt MZ. - The precipitated metal halide can then be filtered from the soluble polymer I.
Et enkelt eksempel på sistnevnte metode innbefatter å behandle en op<p>løsning av polymer I inneholdende bromid-motionet med et overskudd av friskt utfelt sølvklorid. Etter at halogenid-anionutbytningen er fullstendig, fjernes blandingen av sølvklorid og sølvbromid ved filtrering hvilket etterlater en oppløsning av polymer I inneholdende klorid-motionet. Alternativt kan, polymer I hvor Z er sulfat, behandles med. oppløsninger av vannoppløselige kalsium- eller bariumsalter. Således kan sulfat erstattes med nitrat og det utfelte bariumsulfat fjernes. A simple example of the latter method involves treating a solution of polymer I containing the bromide moiety with an excess of freshly precipitated silver chloride. After the halide anion exchange is complete, the mixture of silver chloride and silver bromide is removed by filtration leaving a solution of polymer I containing the chloride moiety. Alternatively, polymer I where Z is sulphate can be treated with. solutions of water-soluble calcium or barium salts. Thus, sulphate can be replaced with nitrate and the precipitated barium sulphate removed.
Eksempel 1 Example 1
Po ly- f ( formimino) -eth yl en )- Poly- f (formimino)-eth yl en )-
En oppløsning av 44 g A 2-oxazolin og 870 mg friskt destillert bortrifluoridetherat i'175 ml renset dimethylformamid ble an-bragt i en trykkreaktor inneholdende en glassforing og systemet ble spylt med nitrogen. Blandingen ble oppvarmet ved 80° C i 5 timer og derpå fortynnet med methanol og filtrert hvilket ga 30 g av poly-((formimino)-ethylenl -polymeren. I en 5 timers reaksjonsperio-de ved 80° C og bortrifluoridetherat-katalysator i et 0,01 molfor-hold til A 2-oxazolin, lå utbyttet av fast polymer i området fra 13,2 % til minst 68%. A solution of 44 g of A 2-oxazoline and 870 mg of freshly distilled boron trifluoride etherate in 175 ml of purified dimethylformamide was placed in a pressure reactor containing a glass liner and the system was flushed with nitrogen. The mixture was heated at 80° C. for 5 hours and then diluted with methanol and filtered to give 30 g of the poly-((formimino)-ethylene) polymer. In a 5 hour reaction period at 80° C. and boron trifluoride etherate catalyst in a 0.01 molar ratio to A 2-oxazoline, the yield of solid polymer was in the range from 13.2% to at least 68%.
Eksempel 2 Example 2
Poly- f( formimino)- ethylen) Poly-f(formimino)-ethylene)
En oppløsning av 217 g (3,06 mol) A<2->oxazolin og 4,6 g (0,03 mol) trifluormethylsulfonsyre i 800 ml renset dimethylformamid i et forseglet rør og under nitrogenatmosfære ble oppvarmet ved 90° C og omrørt i 5 timer.'Etter avkjøling ble blandingen fortynnet med 1200 ml vannfri methanol og produktet ble isolert ved filtrering. Produktet ble vasket med methanol og derpå med ether før tørking under nedsatt trykk. Denne reaksjon ga 150 g poly-((formimino)-ethylen)-. A solution of 217 g (3.06 mol) A<2->oxazoline and 4.6 g (0.03 mol) of trifluoromethylsulfonic acid in 800 ml of purified dimethylformamide in a sealed tube and under nitrogen atmosphere was heated at 90° C. and stirred in 5 hours.'After cooling, the mixture was diluted with 1200 ml of anhydrous methanol and the product was isolated by filtration. The product was washed with methanol and then with ether before drying under reduced pressure. This reaction gave 150 g of poly-((formimino)-ethylene)-.
Eksempel 3 Example 3
Poly- f( acetimino)- ethylen) Poly-f(acetimino)-ethylene)
En 1 g prøve av 2-methyl-A 2-oxazolin ble innført i et Carius-forbrenningsrør med to dråper bortrifluoridetherat (48 %-ig)• Røret ble omhyggelig spylt med nitrogen, flammeforseglet og anb.ragt i en rørovn ved 160° C i 20 timer. Poly-((acetimino)-ethylen)-polymeren er en glassaktig, nesten farveløst harpiks med et smelte-område på 155 - 175° C. Polymeren er lett oppløselig i methylenklorid. A 1 g sample of 2-methyl-A 2-oxazoline was introduced into a Carius combustion tube with two drops of boron trifluoride etherate (48%)• The tube was carefully flushed with nitrogen, flame-sealed and placed in a tube furnace at 160°C for 20 hours. The poly-((acetimino)-ethylene) polymer is a glassy, almost colorless resin with a melting range of 155 - 175° C. The polymer is easily soluble in methylene chloride.
Eksempel 4 Example 4
Poly- f ( butyrimino) - ethylen) : Poly-f(butyrimino)-ethylene):
I dette eksempel polymeriseres et N-acylethylenimin under anvendelse av et enkelt katalysatorsystem som også bevirker: oml^i-ring til et oxazolin-mellomprodukt. In this example, an N-acylethyleneimine is polymerized using a single catalyst system which also causes: conversion to an oxazoline intermediate.
10 ml N-butyrylethylenimin og 0,05 ml bortrifluoridetherat i et evakuert rør- ble oppvarmet ved 60° C i 4 timer. Det dannede faste stoff ble oppløst .1 100. ml kloroform,, felt ved tilsetning av petrole.th.er, gjenoppløst i. kloroform og igjen felt med petrolether. Bunnfallet ble tørket hvilket ga 6,-3 g poly-{ (butyrlmino) -ethylen) med en redusert viskositet på 0,16 i en 1 %-ig oppløsning i benzen, og smeltepunkt 150° C. 10 ml of N-butyrylethyleneimine and 0.05 ml of boron trifluoride etherate in an evacuated tube were heated at 60° C. for 4 hours. The solid formed was dissolved in 100 ml of chloroform, filtered by adding petroleum ether, redissolved in chloroform and filtered again with petroleum ether. The precipitate was dried giving 6.3 g of poly-{(butyrlmino)-ethylene) with a reduced viscosity of 0.16 in a 1% solution in benzene, and melting point 150°C.
På analogt vis, men under anvendelse av: Analogously, but using:
N-benzoylethylenimin N-benzoylethyleneimine
2-i.sopropyl-A 2-oxazolin 2-isopropyl-A 2-oxazoline
2-cycloh.exyl-A<*2->oxazolin 2-cyclohexyl-A<*2->oxazoline
2-nafthyl-A 2-oxazolin 2-naphthyl-A 2-oxazoline
2-p--tclyl-A 2-oxazolin 2-p--tclyl-A 2-oxazoline
fikk man det tilsvarende you got the equivalent
poly-((benzoylimino)-ethylen) poly-((benzoylimino)-ethylene)
poly- ( (isobutyrimino)-ethylen) poly-( (isobutyrimino)-ethylene)
poly-((cyclohexanoylimino)-ethylen) poly-((cyclohexanoylimino)-ethylene)
poly-((nafthoylimino)-ethylen) poly-((naphthoylimino)-ethylene)
poly-((toluoylimino)-ethylen) poly-((toluoylimino)-ethylene)
Eksempel 5 Example 5
Poly-(( benzoylimino)- ethylen) Poly-((benzoylimino)-ethylene)
-3 -3
1,1322 g (7,60 x 10 mol) 2-fenyl-2-oxazolin ble innført 1.1322 g (7.60 x 10 mol) of 2-phenyl-2-oxazoline was introduced
-5 -5
i et Carius-forbrenningsrør med 7,69 x 10 mol bortriflu<p>rid i form av en dimethoxyethanoppløsing. Etter evakuering, spyling med nitrogen'og forsegling ble prøven oppvarmet ved 150° C i 2 timer. 1 g av deni dannede lysegule glassaktige polymer ble malt til et fint pulver og oppløst i 25 ml methylenklorid. Denne oppløsning ble tilsatt til 75 ml n-hexan som ble omrørt kraftig hvorved man fikk et tykt, hvitt bunnfall. Materialet b±e frafUtrert og igjen felt ytterligere to ganger på samme måte hvorved man fikk et fint, hvitt pulver. Gjenvinningen av renset poly((benzoylimino)-ethylen)-polymer var 80 %. Molekylvekten av denne polymer var 7500. in a Carius combustion tube with 7.69 x 10 mol boron trifluoride in the form of a dimethoxyethane solution. After evacuation, flushing with nitrogen and sealing, the sample was heated at 150° C. for 2 hours. 1 g of the light yellow glassy polymer formed was ground to a fine powder and dissolved in 25 ml of methylene chloride. This solution was added to 75 ml of n-hexane, which was stirred vigorously, whereby a thick, white precipitate was obtained. The material was filtered and again filtered two more times in the same way, whereby a fine, white powder was obtained. The recovery of purified poly((benzoylimino)-ethylene) polymer was 80%. The molecular weight of this polymer was 7500.
Eksempel 6 Example 6
Kopolymerisasjon av ekvimolare blandinger av 2-fenyl-2-oxazolin Copolymerization of equimolar mixtures of 2-phenyl-2-oxazoline
og andre 2- substituert- 2- oxazoliner and other 2-substituted-2-oxazolines
Ekvimolare monomerkonsentrasjoner av 2-fenyl-2-oxazolin og henholdsvis 2-benzyl-2-oxazolin; 2-methyl-2-oxazolin; og 2-iso-propyl-2-oxazolin i konsentrasjoner på 1,5 mol/liter i N,N-dimethy1-acetamid ble hver oppvarmet ved 135° C i ca. 2 timer under anvendelse, av 2-fenyl-2-oxazolinium-pe.rklorat som initiator. De dannede poly/- ( (acyliarino).-ethylen)--kopolymerer..var ^tilfeldige med hensyn til innholdet av. N-acylgrupper.. 2-fenyl-2-oxazolin fører til dan-nelsen av N-benzoylderivatet, 2-benzyl-2-oxazolin danner'N-fenyl-acetylderivatet og 2-meth.yl-analogen danner N-ace.tylderivatet. Sammensetningen av :kopolymeren med hensyn til graden av tilfeldig-het påvirkes av.de relative, reaksjonshastigheter av de forskjellige monomerer. Da de dannede polymerer kan være for fremstilling av lineært poly-(ethylenimin), er den forskjellige acylgruppens sammen-setning uten betydning fordi acylgruppene fjernes ved hydrolyse. Equimolar monomer concentrations of 2-phenyl-2-oxazoline and 2-benzyl-2-oxazoline, respectively; 2-methyl-2-oxazoline; and 2-iso-propyl-2-oxazoline at concentrations of 1.5 mol/liter in N,N-dimethyl-acetamide were each heated at 135° C. for approx. 2 hours in use, of 2-phenyl-2-oxazolinium perchlorate as initiator. The poly/- ((acyliarino).-ethylene)--copolymers formed..were ^random with respect to the content of. N-acyl groups.. 2-phenyl-2-oxazoline leads to the formation of the N-benzoyl derivative, 2-benzyl-2-oxazoline forms the N-phenyl-acetyl derivative and the 2-methyl-analog forms the N-acetyl derivative . The composition of the copolymer with respect to the degree of randomness is affected by the relative reaction rates of the various monomers. As the polymers formed can be for the production of linear poly-(ethyleneimine), the composition of the different acyl groups is of no importance because the acyl groups are removed by hydrolysis.
De kan selvsagt reduseres direkte som beskrevet i et etterfølgende They can of course be reduced directly as described in a subsequent section
.eksempel. .Example.
Eksempel 7 Example 7
Poly-( iminoethylen) Poly-(iminoethylene)
Hydrolysen av et poly-((acylimino)-ethylen) utføres ved syre- eller basehydrolyse. (a) Som illustrasjon av basehydrolyse oppvarmes en opp-løsning av 3 g poly-((formimino)-ethylen) og 3 g natriumhydroxyd i 35 ml vann under' omrøring-ved 98° C i 3 timer. Oppløsningen avkjø- ' les til værelsetemperatur og det hvite faste stoff som utfelles, isoleres ved -filtrering, vaskes omhyggelig med vann og tørres under vakuum, hvilket gir 1,6 g poly-(iminoethylen). (b). En 1,29 g prøve av poly- ((acetimino) -ethylen) tilsettes til 50 ml ca. IN natriumhydroxyd. Polymeren er praktisk talt uoppløselig i base ved værelsetemperatur, men etter kokning under tilbakeløp i 2 6 timer blir reaksjonsblandingen homogen. Av-kjøling til værelsetemperatur bringer reaksjonsblandingen til å gelere til en hvit masse. Hydrolysen"er ca. 65 % fullstendig. Det ikke-acylerte''poly-(iminoethylen) renses ved gjentatt f eining, dvs. oppløsning i syre, filtrering av delvis acetylert poly-(iminoethylen) og nøytralisasjon av filtratet. (c) En lg prøve av poly-((acetimino)-ethylen) ble op<p>løst i 50 ml IN svovelsyre. Man fikk en homogen blanding som ble oppvarmet under tilbakeløp i 3,5 timer, idet lukten av saltsyren ble merk-bar. Etter denne tid viste titrering av en prøve med IN natriumhydroxyd en 27 % fullstendig hydrolyse. Etter 21 timers kokning, under tilbakeløp var hydrolysen 38 % fullstendig. The hydrolysis of a poly-((acylimino)-ethylene) is carried out by acid or base hydrolysis. (a) As an illustration of base hydrolysis, a solution of 3 g of poly-((formimino)-ethylene) and 3 g of sodium hydroxide in 35 ml of water is heated with stirring at 98° C. for 3 hours. The solution is cooled to room temperature and the white solid which precipitates is isolated by filtration, washed thoroughly with water and dried under vacuum, which gives 1.6 g of poly-(iminoethylene). (b). A 1.29 g sample of poly-((acetimino)-ethylene) is added to 50 ml approx. IN sodium hydroxide. The polymer is practically insoluble in base at room temperature, but after boiling under reflux for 2 6 hours the reaction mixture becomes homogeneous. Cooling to room temperature causes the reaction mixture to gel to a white mass. The hydrolysis" is about 65% complete. The non-acylated" poly-(iminoethylene) is purified by repeated distillation, i.e. dissolution in acid, filtration of partially acetylated poly-(iminoethylene) and neutralization of the filtrate. (c) A lg sample of poly-((acetimino)-ethylene) was dissolved in 50 ml IN sulfuric acid. A homogeneous mixture was obtained which was heated under reflux for 3.5 hours, the smell of the hydrochloric acid becoming noticeable. After at this time, titration of a sample with 1N sodium hydroxide showed 27% complete hydrolysis.After 21 hours of reflux, hydrolysis was 38% complete.
I alminnelighet fåes en i det vesontlige fullstendig hydrolyse ved å utføre hydrolysen som ovenfor, men i et lukket rø]: ved In general, an essentially complete hydrolysis is obtained by carrying out the hydrolysis as above, but in a closed vessel]: by
120° C, eller høyere, temperaturer. 120° C, or higher, temperatures.
Poly-i (acylimino).-ethylenene} reduseres til N-alkyl- og N-aralkyl-derivater uten forutgående hydrolyse til den frie base. Det foretrukne reduksjonsmiddel er diboran som i det følgende eksempel. Lithiumalumini.umhydrid, llthiumtrimethoxyaluminiumhydrid kan også anvendes. Poly-i (acylimino).-ethylenes} are reduced to N-alkyl and N-aralkyl derivatives without prior hydrolysis to the free base. The preferred reducing agent is diborane as in the following example. Lithium aluminum hydride, lithium trimethoxy aluminum hydride can also be used.
Eksempel 8 Example 8
Poly- ( ethylimino)- ethylen Poly-(ethylimino)-ethylene
Til en oppløsning av 200 ml (3 34 mmol) 1,67M diboran i tetrahydrofuran i en 500 ml kolbe forsynt med tilbakeløpskjøler, dråpetrakt, magnetisk omrøringsstav og holdt under nitrogen tilsettes 17 g (200 mmol/monomerenhet) poly-((acetimino)-ethylen) i 100 ml tetrahydrofuran i løpet av 15 minutter. Temperaturen holdes ved ca. 0° C under tilsetningen. Reaksjonsblandingen holdes så under til-bakeløp i 6 timer. Blandingen får lov til å avkjøle til værelsetemperatur og.50 ml 6M saltsyre tilsettes langsomt gjennom en dråpetrakt. Tetrahydrofuranet fjernes ved destillasjon ved atmosfære-..trykk ettersom hydrogen utvikles (15,5 1, 0,6 mol) fra hydrolysen av amin-borankomplekset. Natriumhydroxyd tilsettes for å felle poly-((ethylimino).-ethylen) . To a solution of 200 ml (3 34 mmol) 1.67 M diborane in tetrahydrofuran in a 500 ml flask equipped with a reflux condenser, dropping funnel, magnetic stir bar and kept under nitrogen is added 17 g (200 mmol/monomer unit) poly-((acetimino)- ethylene) in 100 ml of tetrahydrofuran during 15 minutes. The temperature is kept at approx. 0° C during the addition. The reaction mixture is then kept under reflux for 6 hours. The mixture is allowed to cool to room temperature and 50 ml of 6M hydrochloric acid is added slowly through a dropping funnel. The tetrahydrofuran is removed by distillation at atmospheric pressure as hydrogen is evolved (15.5 1, 0.6 mol) from the hydrolysis of the amine-borane complex. Sodium hydroxide is added to precipitate poly-((ethylimino).-ethylene) .
På analogt vis omsettes hver av polymerene erholdt i Analogously, each of the polymers obtained in
eks.empel 4 for å gi henholdsvis: example 4 to give respectively:
poly-((benzylimino)-ethylen), poly-((benzylimino)-ethylene),
poly-[(isobutylimino)-ethylen), poly-[(isobutylimino)-ethylene),
poly-((nafthylmethylimino)-ethylen). poly-((naphthylmethylimino)-ethylene).
Eksempel 9 Example 9
Poly- f ( methylin nino) - ethylen- hydroklorid) Poly- f ( methylin nino) - ethylene hydrochloride)
2,5 g poly-(iminoethylen) tilsettes langsomt til 12 g 2.5 g of poly-(iminoethylene) is added slowly to 12 g
90 %-ig maursyre, og 5,5 g 38 %-ig vandig formaldehyd tilsettes. 90% formic acid and 5.5 g of 38% aqueous formaldehyde are added.
Etter at blandingen har vært oppvarmet ved 100° C i 72 timer, avkjø-les den og 5,5 ml konsentrert saltsyre tilsettes. Blandingen inndampes til tørrhetuunder nedsatt trykk, hvilket gir 5 g poly((methylimino)-ethylen-hydroklorid}. After the mixture has been heated at 100° C. for 72 hours, it is cooled and 5.5 ml of concentrated hydrochloric acid is added. The mixture is evaporated to dryness under reduced pressure, which gives 5 g of poly((methylimino)-ethylene hydrochloride}.
Eksempel 10 Example 10
Poly- (( dimethyl imino) - ethylen- klorld)- Poly- ((dimethyl imino) - ethylene- chlorold)-
50.0- mg (5,4 mmol) poly-((methylimino)-ethylen-hydroklorid) oppløses i. 50. ml methanol inneholdende 291 mg (5,4 mmol) natrium- 50.0 mg (5.4 mmol) of poly-((methylimino)-ethylene hydrochloride) is dissolved in 50 ml of methanol containing 291 mg (5.4 mmol) of sodium
methoxyd. Oppløsningen avkjøles i. et aceton-tørrisbad, og 10 g meth.ylenklorid kondenseres 1 oppløsningen. Denne blanding oppvarmes i e.t forseglet rør ved 80° C i 5 timer. Denne blanding inndampes til tørrhet under nedsatt trykk, og produktet taes opp i'3 ml vannfri..methanol og filtreres, og oppløsningen inndampes til tørrhet. Oppløsning av produktet i methanol, filtrering med påfølgende inndam-ning til tørrhet gjentaes flere ganger. Filtratet inndampes under nedsatt trykk hvilket gir 400 mg poly- ((dimethylimino)-ethylen-klorid). methoxyd. The solution is cooled in an acetone-dry ice bath, and 10 g of methylene chloride is condensed in the solution. This mixture is heated in a sealed tube at 80° C for 5 hours. This mixture is evaporated to dryness under reduced pressure, and the product is taken up in 3 ml of anhydrous methanol and filtered, and the solution is evaporated to dryness. Dissolution of the product in methanol, filtration followed by evaporation to dryness is repeated several times. The filtrate is evaporated under reduced pressure, which gives 400 mg of poly-((dimethylimino)-ethylene chloride).
Eksempel 11 Example 11
Poly- ( dimethylimino)- ethylen- bromid Poly-(dimethylimino)-ethylene bromide
En oppløsning av 860 mg (20 milliekvivalenter) poly-(iminoethylen) i 30 ml methanol behandles med 9,5 g (100 mmol) methylbromid ved 50° C i 3 timer. Reaksjonsblandingen inndampes til tørrhet under nedsatt trykk. Residuet behandles imed 1,08 g (20 mmol) nstrium-methoxyd i 10 ml methanol og inndampes til tørrhet. Residuet taes opp i 30 ml vannf ri methanol og behandles med 9)5 g (100^ mmol) methylbromid, og oppløsningen oppvarmes ved 50° C i 3 timer. Etter inndampning taes produktet opp i vann, og oppløsningen underkastes ultrafiltrering gjennom et "VM 2 Diaflo Ultrafilter". Det tilbake-holdte inndampes så under nedsatt trykk hvilket gir 2,8 g poly-((dimethylimino)-ethylen-bromid}. A solution of 860 mg (20 milliequivalents) of poly-(iminoethylene) in 30 ml of methanol is treated with 9.5 g (100 mmol) of methyl bromide at 50° C. for 3 hours. The reaction mixture is evaporated to dryness under reduced pressure. The residue is treated with 1.08 g (20 mmol) of sodium methoxide in 10 ml of methanol and evaporated to dryness. The residue is taken up in 30 ml of anhydrous methanol and treated with 9.5 g (100 mmol) of methyl bromide, and the solution is heated at 50° C. for 3 hours. After evaporation, the product is taken up in water, and the solution is subjected to ultrafiltration through a "VM 2 Diaflo Ultrafilter". The retentate is then evaporated under reduced pressure, which gives 2.8 g of poly-((dimethylimino)-ethylene bromide}).
Eksempel 12 Example 12
Poly-(( dimethylimino)- ethylen- methosulfat) Poly-((dimethylimino)- ethylene methosulfate)
0,5 g poly-((methylimino)-ethylen-hydroklorid) oppløses i '50 ml methanol inneholdende 0,29 g natriummethoxyd. Oppløsningen inndampes til ca. 20 ml og 0,7 g dimethylsulfat tilsettes. Oppløs-ningen oppvarmes så i 6 timer ved 50° C., og produktet felles ved å helle oppløsningen i et stort volum aceton eller ved å fordampe methanolen fulgt av acetonvasking. Produktet tørkes ved værelsetemperatur under nedsatt trykk. 0.5 g of poly-((methylimino)-ethylene hydrochloride) is dissolved in 50 ml of methanol containing 0.29 g of sodium methoxy. The solution is evaporated to approx. 20 ml and 0.7 g of dimethylsulphate are added. The solution is then heated for 6 hours at 50° C., and the product precipitated by pouring the solution into a large volume of acetone or by evaporating the methanol followed by acetone washing. The product is dried at room temperature under reduced pressure.
E ksempel 13 Example 13
Poly- f{( 2- hydroxyethyl)- methylimino}- ethylen- klorid) Poly- f{( 2- hydroxyethyl)- methylimino}- ethylene- chloride)
Fremgangsmåten i eksempel 10 ble fulgt, men der ble anvendt 15,8 g ethylenklorhydrin isteden for 10 g methylklorid. Blandingen ble oppvarmet ved 80° C i 5 - 7 timer og derpå befridd for oppløsningsmidler og overskudd av reagenser ved avdrivning under The procedure in example 10 was followed, but 15.8 g of ethylene chlorohydrin was used instead of 10 g of methyl chloride. The mixture was heated at 80° C. for 5 - 7 hours and then freed from solvents and excess reagents by stripping under
O O
ne.ds.att trykk...Residuet var .poly-(f.(2-hydroxyethyl.)-methylimino)-ethylen-klorid) . ne.ds.that pressure...The residue was .poly-(f.(2-hydroxyethyl.)-methylimino)-ethylene-chloride) .
På analogt vis anvendes en. ekvivalent mengde propylenklorhydrin. eller sek-propylenklorhydrin istedenfor ethylenklorhydri-net hvorved man f år. poly-({.( l-methyl-2-hydroxyethyl) -methylimino)-ethylen-klorid)- og poly-({ ( 2-liydroxypropyl) -methylimino)-ethylen-klorid)-. Analogously, a is used. equivalent amount of propylene chlorohydrin. or sec-propylene chlorohydrin instead of ethylene chlorohydrin, which gives poly-({.(1-methyl-2-hydroxyethyl)-methylimino)-ethylene chloride)- and poly-({((2-liydroxypropyl)-methylimino)-ethylene chloride)-.
Eksempel 14 Example 14
Poly- { ( 2- hydroxyethylimino)- ethylen) Poly- { ( 2- hydroxyethylimino)- ethylene)
0,5 g poly-(iminoethylen) fra eksempel 7 oppløses i 50 ml methanol og oppvarmes med 0,3 5 g ethylenoxyd i et forseglet rør under nitrogen ved 60° C i 3 timer. Oppløsningsmidlet og overskudd av epoxyd fjernes ved avdrivning under nedsatt trykk. Residuet var poly- ((2-h.ydroxyethylimino) -ethylen) . 0.5 g of poly-(iminoethylene) from example 7 is dissolved in 50 ml of methanol and heated with 0.35 g of ethylene oxide in a sealed tube under nitrogen at 60° C. for 3 hours. The solvent and excess epoxy are removed by stripping under reduced pressure. The residue was poly-((2-hydroxyethylimino)-ethylene).
Eksempel 15 Example 15
Poly- f{( 2- hydroxybutyl)- 2- hydroxyethylimino)- ethylen- bromid) Poly- f{( 2- hydroxybutyl)- 2- hydroxyethylimino)- ethylene- bromide)
Poly-(( 2-hyd.roxyethylimino)-ethylen) fra det foregående eksempel oppvarmes i 50 ml aceton med 20 g 2-hydroxybutylbromid ved 80 - 90° C i et* forseglet rør i 6 - 8 timer. Poly-((2-hydroxyethylimino)-ethylene) from the previous example is heated in 50 ml of acetone with 20 g of 2-hydroxybutyl bromide at 80 - 90° C in a* sealed tube for 6 - 8 hours.
Produktet utvinnes -som før ved fjernelse av oppløsnings-middel og overskudd av reagens under nedsatt trykk. Residuet er poly-({(2-hydroxybutyl)-2-hydroxyethylimino)-ethylenbromid). The product is recovered - as before by removing solvent and excess reagent under reduced pressure. The residue is poly-({(2-hydroxybutyl)-2-hydroxyethylimino)-ethylene bromide).
Eksempel 16 Example 16
Poly- / ( methylimino) - ethy. len- hydroklorid"! Poly-/(methylimino)-ethy. lin-hydrochloride"!
En blanding av 25 g poly-(formiminoethylen), 504 g 97 - 100 %-ig maursyre og 118 g 38 %-ig vandig formaldehyd (formalin) ble oppvarmet ved 100° C i 60 timer..Reaksjonsblandingen ble avkjølt, 210 ml konsentrert saltsyre ble tilsatt og blandingen ble inndampet til tørrhet under nedsatt trykk ved 50 C. Produktet vaskes med methanol og derpå ether, og tørkes, hvorved man får 34,6 g poly-r(methylimino)-ethylen-hydrokloridy. A mixture of 25 g of poly-(formiminoethylene), 504 g of 97-100% formic acid and 118 g of 38% aqueous formaldehyde (formalin) was heated at 100° C. for 60 hours. The reaction mixture was cooled, 210 ml concentrated hydrochloric acid was added and the mixture was evaporated to dryness under reduced pressure at 50 C. The product is washed with methanol and then ether, and dried, thereby obtaining 34.6 g of poly-r(methylimino)-ethylene hydrochloride.
Eksempel 17 Example 17
Poly-'( methylimino)-ethylen/ Poly-'(methylimino)-ethylene/
En' oppløsning inneholdende 0,325 mol natriumhydroxyd fremstilles, ved å oppløse 17,55 g natriummethoxyd i 400 ml vann. Til dette tilsettes 28,6 g (0,31 mol) poly-^(methylimino)-ethylen~hydro klorid] , og totalvolurae,t a<y>oppløsningen bringes opp til 500 ml ved tils.etning av vann.'Oppløsningen avsaltes så og befries også for eventuelt produkt med .en. molekylvekt på under 1000 under anvendelse av en. "Amicon." filtercelle forsynt med et "UM2 Diaflo Ultraf ilter."., Deretter inndampes oppløsningen under nedsatt trykk ved 50° C hvilket gir 16 g poly-((methylimino)-ethylen}. A solution containing 0.325 mol of sodium hydroxide is prepared by dissolving 17.55 g of sodium methoxide in 400 ml of water. To this is added 28.6 g (0.31 mol) poly-^(methylimino)-ethylene-hydrochloride], and the total volume of the solution is brought up to 500 ml by adding water. The solution is then desalted and is also exempt from any product with .en. molecular weight of less than 1000 using a. "Amicon." filter cell equipped with a "UM2 Diaflo Ultrafilter.", The solution is then evaporated under reduced pressure at 50° C. which gives 16 g of poly-((methylimino)-ethylene}.
Eksempel . 18 Example . 18
Poly- f( dimethylimino)-ethylen-bromid} Poly-f(dimethylimino)-ethylene bromide}
En opplsøning av 21,7 g (0,38 mol) poly-[(methylimino)-ethylen} i 130 ml vannfri methanol avkjøles og 364 g (3,8 mol) kon-densert methylbromid tilsettes. Blandingen i en glassf6ret try^k-reaktor oppvarmes ved. 50° C i 5 timer. Etter at blandingen er av-kjølt, isoleres produktet ved filtrering, vaskes med ether og tørres under nedsatt trykk hvorved man får 58 g poly-((dimethylimino)-ethylen-bromid}. A solution of 21.7 g (0.38 mol) of poly-[(methylimino)-ethylene} in 130 ml of anhydrous methanol is cooled and 364 g (3.8 mol) of condensed methyl bromide is added. The mixture in a glass-lined pressure reactor is heated by 50° C for 5 hours. After the mixture has cooled, the product is isolated by filtration, washed with ether and dried under reduced pressure, thereby obtaining 58 g of poly-((dimethylimino)-ethylene bromide).
Eksempel 19 Example 19
Poly- f ( dimethylimino) - ethylen- klorid)- Poly- f ( dimethylimino)- ethylene- chloride)-
En oppløsning av 58 g poly-((dimethylimino)-ethylenbromid) A solution of 58 g of poly-((dimethylimino)-ethylene bromide)
(0,38 mol) i 3 liter vann føres langsomt (10 ml/min) gjennom en 770 ml kolonne av 2 00 - 4 00 mesh "AG1-X8" kvartært ammoniumkloridharpiks (1078 milliekvivalenter Cl~). Etter at 4200 ml avløp var oppsamlet, ble det inndampet under nedsatt trykk ved 50 - 55° C, og tørret (0.38 mole) in 3 liters of water is passed slowly (10 ml/min) through a 770 ml column of 2 00 - 4 00 mesh "AG1-X8" quaternary ammonium chloride resin (1078 milliequivalents of Cl~). After 4200 ml of effluent had been collected, it was evaporated under reduced pressure at 50 - 55° C, and dried
hvorved man fikk 37 g poly- ((dimethylimino) -ethylen-klorid)'■. whereby 37 g of poly-((dimethylimino)-ethylene chloride)'■ was obtained.
Eksempel 20 Example 20
Fremstilling av poly-(( dimethylimino)- ethyl en- ascorbat) Production of poly-((dimethylimino)-ethyl en-ascorbate)
5,0 g poly-/(dimethylimino) -"ethylen-klorid' oppløses i 75 ml destillert' vann og føres gjennom en kolonne inneholdende 100 g (0,5 mol Cl utbytningskapasitet) av en polystyrenharpiks, hvori benzenringen er substituert med 4-oxotrimethylammoniumhydroxyd ("Bio Rad AG 1 x 8"). Seks kolonnevolum eluat (450 ml) inneholdende poly-((dimethylimino)-ethylen-hydroxyd) ble oppsamlet, inndampet til 150 ml, avkjølt til 15° C og nøytralisert med 8,8 g (0,05 mol) ascorbinsyre, U.S.P. Den klare nøytraliserte oppløsning ble så skallfrosset, og lyofilisert hvorved man fikk et hvitt fast stoff som var lett pulveriserbart. 5.0 g of poly-(dimethylimino)-"ethylene chloride" is dissolved in 75 ml of distilled water and passed through a column containing 100 g (0.5 mol Cl exchange capacity) of a polystyrene resin, in which the benzene ring is substituted with 4- oxotrimethylammonium hydroxide ("Bio Rad AG 1 x 8"). Six column volumes of eluate (450 ml) containing poly-((dimethylimino)-ethylene hydroxide) were collected, evaporated to 150 ml, cooled to 15°C and neutralized with 8.8 g (0.05 mole) of ascorbic acid, U.S.P. The clear neutralized solution was then shell-frozen and lyophilized to give a white solid which was easily pulverized.
De andre polymerer ifølge oppfinnelsen kan likeledes over-føres til ascorbatsaltet, eller ved anvendelse av andre syrer inneholdende, fysiologisk godtagbare anioner istedenfor ascorbinsyren, The other polymers according to the invention can likewise be transferred to the ascorbate salt, or by using other acids containing physiologically acceptable anions instead of the ascorbic acid,
fåes andra salter som ovenfor1..beskrevet. other salts are obtained as described above1..
Eksempel 21 Example 21
5 , 6- dlh:ydro- 4H- T, 3- oxazin 5, 6- dlh:ydro- 4H- T, 3- oxazine
En blanding av 94 g (1,13 mol) t-butyliscnitril, 85 g (1,13 mol), friskt destillert 3-aminopropanol, og 7,4 g (0,055 mol) sølvcyanid ble omrørt ved 90° C under et nitrogenteppe i 16 timer. Produktet ble isolert fra reaksjonsblandingen ved destillasjon ved 45 mm og så renset ved gjentatt fraksjonering. Vanligvis er to slike fraksjoneringen tilstrekkelig til å gi et rent produkt. På denne måte fåes 44 g rent 5,6-dih.ydro-4H-l, 3-oxazin, kokepunkt 58°C/58 mm, nD1,4485, og lagres over molekylsikter type 4A og under nitrogen. A mixture of 94 g (1.13 mol) t-butyl iscnitrile, 85 g (1.13 mol), freshly distilled 3-aminopropanol, and 7.4 g (0.055 mol) silver cyanide was stirred at 90° C. under a blanket of nitrogen in 16 hours. The product was isolated from the reaction mixture by distillation at 45 mm and then purified by repeated fractionation. Usually two such fractionations are sufficient to give a pure product. In this way, 44 g of pure 5,6-dihydro-4H-1,3-oxazine, boiling point 58°C/58 mm, nD 1.4485 are obtained, and are stored over molecular sieves type 4A and under nitrogen.
Eksempel 22 Example 22
Poly-(( formimino)- trimethylen) Poly-((formimino)-trimethylene)
En oppløsning av 44 g (0,52 mol) 5,6-dihydro-4H-l,3-oxazin i. 14 0 ml renset dimethylf ormamid anbringes -i ..et trykkrør og 1,52 g (0,011 mol) jodmethan tilsettes. Systemet spyles med nitrogen, forsegles og oppvarmes ved. 80° C i 5 timer. Blandingen avkjø-les og fortynnes med ti volum ether, og produktet isoleres ved filtrering. Produktet vaskes med ether. og tørres under nedsatt trykk ved 75° C hvilket gir 40 g poly (formimino)-trimethylen, smeltepunkt under sp.altning 111 112° C. A solution of 44 g (0.52 mol) of 5,6-dihydro-4H-1,3-oxazine in 140 ml of purified dimethylformamide is placed in a pressure tube and 1.52 g (0.011 mol) of iodomethane is added . The system is flushed with nitrogen, sealed and heated with wood. 80° C for 5 hours. The mixture is cooled and diluted with ten volumes of ether, and the product is isolated by filtration. The product is washed with ether. and dried under reduced pressure at 75° C, which gives 40 g of poly(formimino)-trimethylene, melting point under sp.altning 111 112° C.
Eksempel 2 3 ; Example 2 3 ;
Polyf( methylimino)- trimethylen- hydroklorid) Poly(methylimino)trimethylene hydrochloride)
En blanding av 53 g poly-(f o.rmiminotrimethylen) , 1320 g A mixture of 53 g of poly-(formiminotrimethylene), 1320 g
97 - 100 %-ig maursyre, og 308 g 38 %-ig vandig formaldehyd oppvarmes ved 100° C i 120 timer. Etter at oppløsningen er avkjølt tilsettes 650 ml konsentrert saltsyre, og blandingen inndampes til tørrhet ved 50° C under nedsatt trykk. Residuet tritureres med 400 ml methanol, isoleres ved filtrering, vaskes med ether og tørres under nedsatt trykk hvilket gir 67 g poly-((methylimino)-trimethylen-hydroklorid)-. 97 - 100% formic acid and 308 g of 38% aqueous formaldehyde are heated at 100° C. for 120 hours. After the solution has cooled, 650 ml of concentrated hydrochloric acid are added, and the mixture is evaporated to dryness at 50° C. under reduced pressure. The residue is triturated with 400 ml of methanol, isolated by filtration, washed with ether and dried under reduced pressure, which gives 67 g of poly-((methylimino)-trimethylene hydrochloride)-.
Eksem pel 24 Example number 24
Poly- ( methyiimiho). -trim ethy len Poly- ( methyiimiho). -trim ethyl len
En oppløsning av 67 g (630 milliekvivalenter) poly ((methylimino),-trimethylen-hydroklorld)- i 600 ml vann behandles med 39 g (0 ,72 mol), natr.iummeth.oxyd. Dette ' er'simpelt hen en lett måte å fremstille en oppløsning av natriumhydroxyd med nøyaktig normali-tet. Et tilsvarende volum av en standardisert oppløsning av natriumhydroxyd er like vel egnet.. Oppløsningen avsaltes og polymer med molekylvekt under 1000- fjernes under anvendelse av en "Amicon" fi.ltercelle forsynt med et "UM2 'Diaflo Ultraf ilter" . Tilslutt inndampes oppløsningen ved 50° C under nedsatt trykk hvilket gir 45 g poly-((methylimino).-trimeth<y>len}. A solution of 67 g (630 milliequivalents) of poly((methylimino),-trimethylene-hydrochlorid)- in 600 ml of water is treated with 39 g (0.72 mol), sodium methoxyd. This is simply an easy way of preparing a solution of sodium hydroxide of exact normality. An equivalent volume of a standardized solution of sodium hydroxide is equally suitable. The solution is desalted and polymer with a molecular weight below 1000 is removed using an "Amicon" filter cell equipped with a "UM2 'Diaflo Ultra filter". Finally, the solution is evaporated at 50° C under reduced pressure, which gives 45 g of poly-((methylimino).-trimeth<y>lene}.
Eksempel 25 Example 25
Polyf( dimethylimino)- trimethylen- bromid) Poly(dimethylimino)- trimethylene- bromide)
En oppløsning av 14 g (200 milliekvivalenter) poly-((methylimino)-trimethylen} og 76 g (0,8 mol) brommethan i 90 ml methanol oppvarmes ved 50° C i en forseglet reaktor i 5 timer. Produktet isoleres ved filtrering, vaskes med methanol og derpå med ether, og tørres under nedsatt trykk hvilket gir 28 g poly-((dimethylimino)-trimethylen-bromid}. A solution of 14 g (200 milliequivalents) of poly-((methylimino)-trimethylene} and 76 g (0.8 mol) of bromomethane in 90 ml of methanol is heated at 50° C. in a sealed reactor for 5 hours. The product is isolated by filtration, washed with methanol and then with ether, and dried under reduced pressure which gives 28 g of poly-((dimethylimino)-trimethylene bromide}).
Eksempel 2 6 Example 2 6
Poly- f( dimethylimino)- trimethylen- klorid) Poly-f(dimethylimino)-trimethylene- chloride)
En oppløsning av 28 g (170 milliekvivalenter) poly-((dimethylimino)-trimethylen-bromid) i 1400 ml vann føres langsomt gjennom en kolonne inneholdende 1000 ml "Dowex 1-X2" (Cl~ formen) harpiks (0,8 mol). Etter at oppløsningen har passert gjennom, føres vann gjennom kolonnen inntil avløpet gir en negativ sølvnitratprøve. Det totale avløp inndampes til tørrhet, og produktet tørres under nedsatt trykk hvilket gir 17,2 g poly-((dimethylimino)-trimethylenklorid}. A solution of 28 g (170 milliequivalents) of poly-((dimethylimino)-trimethylene bromide) in 1400 ml of water is passed slowly through a column containing 1000 ml of "Dowex 1-X2" (Cl~ form) resin (0.8 mol) . After the solution has passed through, water is passed through the column until the effluent gives a negative silver nitrate test. The total effluent is evaporated to dryness, and the product is dried under reduced pressure, which gives 17.2 g of poly-((dimethylimino)-trimethylene chloride}.
Eksempel 27 '" ; Poly- f{ methyl-( 3- hydroxypropyl)- imino}- trimethylen- bromid) Example 27 '" ; Poly-f{methyl-(3-hydroxypropyl)-imino}-trimethylene-bromide)
En oppløsning av 142 mg (2 milliekvivalenter) poly-((methylimino)-trimethylen).og 1,12 g (8 mmol) 3-brompropanol i 5 ml renset dimethylformamid oppvarmes ved 7 5° C i 24 timer. Produktet isoleres ved filtrering, vaskes med aceton og tørres under nedsatt trykk hvilket gir 330 mg poly [{methyl-(3-hydroxypropyl)-imino }-trimethylen-bromid }. A solution of 142 mg (2 milliequivalents) of poly-((methylimino)-trimethylene) and 1.12 g (8 mmol) of 3-bromopropanol in 5 ml of purified dimethylformamide is heated at 75° C. for 24 hours. The product is isolated by filtration, washed with acetone and dried under reduced pressure, which gives 330 mg of poly[{methyl-(3-hydroxypropyl)-imino}-trimethylene bromide}.
Eksempel 28 Example 28
Poly- {( meth yl'-'^^(:3-hydroxypro py 1) - imino' )-t rimeth y len- klor id Poly-{(meth yl'-'^^(:3-hydroxypro py 1)- imino' )-trimeth y len- chlor id
En oppløsning av 315 mg 41/5 milliekvivalenter) poly- A solution of 315 mg 41/5 milliequivalents) poly-
(Imethyl-(3^hydro.xyprapYl)..T imino}-trim i .16 ral vann føres langsomt gjennom en kolonne av 9 ml "Dowex 1- X2" ionebytte-harpi.ks (7,2 mmol kloridi.on) , og derpå føres vann gjennom inntil avløpet gir. en negativ prøve, på kloridlon. Det forenede avløp inndampes til tørrhet ved 50° C under nedsatt trykk hvilket gir 230 mg poly-({methyl-(3-hydroxypropyl).-imino)-trimethylenklorid} . (Imethyl-(3^hydro.xyprapYl)..Timino}trim in .16 ral water is passed slowly through a column of 9 ml "Dowex 1-X2" ion exchange resins (7.2 mmol chloride ion) , and then water is passed through until the effluent gives a negative sample, for chloride ion. The combined effluent is evaporated to dryness at 50° C. under reduced pressure which gives 230 mg of poly-({methyl-(3-hydroxypropyl).-imino)- trimethylene chloride} .
I det foregående eksempel fremstilles en polymer med. formel III hvor R-^ og R2begge er 3-hydroxypropyl. De følgende trekeksemp-ler vil vise hvorledes polymerer med formel III kan fremstilles med R-j_.=3-hydroxypropyl og R2= CH^. I disse eksempler utgjør R-^og R2 henholdsvis 5 - 95 % og 95 - 5 % av summen av Ri + R0, og er fordelt tilfeldig langs polymerkjeden. In the preceding example, a polymer is produced with formula III wherein R 1 and R 2 are both 3-hydroxypropyl. The following three examples will show how polymers of formula III can be prepared with R 1 = 3-hydroxypropyl and R 2 = CH 2 . In these examples, R 1 and R 2 constitute respectively 5 - 95% and 95 - 5% of the sum of R 1 + R 0 , and are distributed randomly along the polymer chain.
Eksempel 29 Example 29
Polymer med formel III hvor R^= 3-hydroxypropyl og R2~methyl Polymer with formula III where R^= 3-hydroxypropyl and R2~methyl
( tilfeldig fordeling i et 5:95 forhold) (random distribution in a 5:95 ratio)
En oppløsning av 462 mg (6 milliekvivalenter) poly-((methylimino)-trimethylen)- og 41 mg (300umol) 3-brompropanol i 12 A solution of 462 mg (6 milliequivalents) of poly-((methylimino)-trimethylene) and 41 mg (300 umol) of 3-bromopropanol in 12
ml dimethylformamid oppvarmes ved 75° C i .24 timer. Blandingen av-kjøles og 2,9 g (30 mmol) methylbromid tilsettes. Reaksjonsblandingen. oppvarmes ved 50° C i 3 timer. Produktet isoleres ved å inn-dampe reaksjonsblandingen under nedsatt trykk og så vaske med ether og tørre under nedsatt trykk. Utbytning av bromid-motionet med kloridionet utføres ; .på vanlig måte under anvendelse av en ionebytteharpiks'som beskrevet ovenfor.. ml of dimethylformamide is heated at 75° C. for .24 hours. The mixture is cooled and 2.9 g (30 mmol) of methyl bromide are added. The reaction mixture. heated at 50° C. for 3 hours. The product is isolated by evaporating the reaction mixture under reduced pressure and then washing with ether and drying under reduced pressure. Exchange of the bromide ion with the chloride ion is carried out; .in the usual manner using an ion exchange resin'as described above..
Eksempel 30 Example 30
Polymer med formel III hvor R^_ ,= 3-hydroxypropyl og R2= Polymer of formula III where R 2 = 3-hydroxypropyl and R 2 =
methyl ( tilfel dig fordeling i et 50:50 forhold) methyl (random distribution in a 50:50 ratio)
En' 'oppløsning av 213 mg (3 milliekvivalenter) poly-((methylimino)-trimethylen)- og 209 mg (1,5 mmol) 3-brompropanol oppvarmes ved 75° C i 24 timer. Reaksjonsblandingen avkjøles og 1,5 g methylbromid tilsettes. Reaksjonsblandingen oppvarmes ved 50° C i 3 timer og opparbeides så på den ovenfor beskrevne måte. A solution of 213 mg (3 milliequivalents) of poly-((methylimino)-trimethylene) and 209 mg (1.5 mmol) of 3-bromopropanol is heated at 75° C. for 24 hours. The reaction mixture is cooled and 1.5 g of methyl bromide is added. The reaction mixture is heated at 50° C. for 3 hours and then worked up in the manner described above.
Eksempel 31 Example 31
Polymer med formel III hvor R^= 3-hydroxypropyl og R2= Polymer of formula III where R^= 3-hydroxypropyl and R2=
methy l ( tilfeldig fordeling - i et 95: 5 forhold)' methy l (random distribution - in a 95:5 ratio)'
En oppløsning av 142 mg (2 milliekvivalenter) poly-((methylimino)„-trimethylen}- og 264 mg (1,9 mmol). 3-brompropanol oppvarmes ved 75° C i 16 timer. Etter at blandingen er avkjølt, til settes 1 g methylbromid og blandingen oppvarmes.ved 50° C i.12 timer. Reaks jonsblandingen opparbeides.<p>å den ovenfor beskrevne .måte. A solution of 142 mg (2 milliequivalents) of poly-((methylimino)„-trimethylene} and 264 mg (1.9 mmol). 3-bromopropanol is heated at 75° C. for 16 hours. After the mixture has cooled, add 1 g of methyl bromide and the mixture is heated at 50° C for 12 hours. The reaction mixture is worked up in the manner described above.
Eksempel 32 Example 32
P oly~ f {methyl - ( 3-methoxypropyl) - imino) - tr ime thy 3. en-klor id} P oly~ f {methyl - ( 3-methoxypropyl) - imino) - tri ime thy 3. en-chlor id}
En oppløsning av 284 .mg (4 milliekvivalenter) poly-((methylimino),-trimethylen)- og 2,45 g (16 mmol) 3-methoxypropylbromid i. 15 ml dimethylf ormamid oppvarmes ved 75° C i 16 timer. Produktet isoleres ved filtrering, vaskes med ether og tørres under nedsatt trykk. Produktet oppløses i 25 ml vann og bromid-motionet utbyttes med kloridion ved ionebytning som beskrevet ovenfor. På denne måte fåes 450 mg poly-({methyl-(3-methoxypropyl)-imino}-trimethylenklorid). A solution of 284 mg (4 milliequivalents) of poly-((methylimino),-trimethylene) and 2.45 g (16 mmol) of 3-methoxypropyl bromide in 15 ml of dimethylformamide is heated at 75° C. for 16 hours. The product is isolated by filtration, washed with ether and dried under reduced pressure. The product is dissolved in 25 ml of water and the bromide ion is exchanged with chloride ion by ion exchange as described above. In this way, 450 mg of poly-({methyl-(3-methoxypropyl)-imino}-trimethylene chloride) are obtained.
For syntesen av polymerer med formel III hvor R±og R2er henholdsvis 3~methoxypropyl og methyl i forhold varierende fra 5:95 til 95:5, eir fremgangsmåten i det vesentlige som beskrevet ovenfor hvor poly((methylimino)-trimethylen) omsettes med én begrensende mengde' 3-methoxypropylbromid og derpå med et overskudd av methylbromid. For the synthesis of polymers of formula III where R± and R2 are respectively 3~methoxypropyl and methyl in ratios varying from 5:95 to 95:5, the procedure is essentially as described above where poly((methylimino)-trimethylene) is reacted with one limiting amount of 3-methoxypropyl bromide and then with an excess of methyl bromide.
Eksempel 3 3 Example 3 3
Poly-( Oflathyl-( 3- methylthiopropyl)- imino}- trimethylenklorid). Poly-(Oflathyl-(3-methylthiopropyl)-imino}-trimethylene chloride).
En oppløsning av 426 mg (6 milliekvivalenter) poly-((meth<y>limino)-trimeth<y>len) og 4,06 g 3-methylthiopropylbfomid i 15 ml dimethylformamid oppvarmes ved 75° C i 24 timer. Produktet isoleres ved filtrering, taes opp i 30 ml vann og føres gjennom en ■ kolonne med 45 ml "Dowex 1-X2" ionebytteharpiks (36 mmol kloridion). Inndampning av det vandige eluat gir 650 mg poly({methyl-(3-methyi-thiopropyl)-iminoj-trimethylen-klorid). A solution of 426 mg (6 milliequivalents) of poly-((meth<y>limino)-trimeth<y>lene) and 4.06 g of 3-methylthiopropylformamide in 15 ml of dimethylformamide is heated at 75° C. for 24 hours. The product is isolated by filtration, taken up in 30 ml of water and passed through a ■ column with 45 ml of "Dowex 1-X2" ion exchange resin (36 mmol of chloride ion). Evaporation of the aqueous eluate gives 650 mg of poly({methyl-(3-methyl-thiopropyl)-imino-trimethylene chloride).
For...syntesen av polymerer med formel III hvor R-^og R2er henholdsvis 3-methylthiopropyl og methyl i forhold varierende fra 5:95 til 95:5, er fremgangsmåten i det vesentlige som beskrevet ovenfor hvor poly-((methylimino)-trimethylen) omsettes med en begrensende mengde 3-methylthiopropylbromid og derpå med et overskudd av methylbromid. For...the synthesis of polymers of formula III where R-^ and R2 are respectively 3-methylthiopropyl and methyl in ratios varying from 5:95 to 95:5, the procedure is essentially as described above where poly-((methylimino)- trimethylene) is reacted with a limiting amount of 3-methylthiopropyl bromide and then with an excess of methyl bromide.
Eksempel 34 Example 34
Poly- f{ methyl-(3-a mmoriiopropyl)-im ino x -1r ime thy1en-d i k1or i d) Poly-f{ methyl-(3-aminopropyl)-iminox-1rimethy1ene-dichlorind)
En oppløsning av 568 mg (8 milliekvivalenter) poly-((methyl imino).-trimethylen) og 8,6 g (30 mmol) 3-f thalimidopropyl-Bromid i. 25 ml dimethylf ormamid oppvarmes ved 7 5° C i 18 timer. Produktet isoleres, ved filtrering, suspenderes i 10 ml methanol og behandles med 1 g vannf ritt hydrazin ved 50° C i. 3 timer. Blandingen inndampes under nedsatt trykk., syres med fortynnet saltsyre, trltureres med ether og isoleres ved filtrering. Produktet taes opp i. vann og føres gjennom en 45 ml., kolonne med "D.owex l-X2"ione~bytteharplks. (36 mmol kloridion)... Inndampning av det vandige eluat gir poly-({methyl-(3-ammoniopropyl)-imino}-trimethylen-diklorid}... A solution of 568 mg (8 milliequivalents) of poly-((methyl imino).-trimethylene) and 8.6 g (30 mmol) of 3-phthalimidopropyl bromide in 25 ml of dimethylformamide is heated at 75°C for 18 hours . The product is isolated, by filtration, suspended in 10 ml of methanol and treated with 1 g of anhydrous hydrazine at 50° C. for 3 hours. The mixture is evaporated under reduced pressure, acidified with dilute hydrochloric acid, triturated with ether and isolated by filtration. The product is taken up in water and passed through a 45 ml column with "Dowex 1-X2" ion-exchange resins. (36 mmol chloride ion)... Evaporation of the aqueous eluate gives poly-({methyl-(3-ammoniopropyl)-imino}-trimethylene dichloride}...
Alternativt oppvarmes en oppløsning av 568 mg (8 milliekvivalenter). poly-((methylimino)-trimethylen) og 6,3 g (40 mmol) l-brom-3-klorpropan i 20 ml dimethylformamid ved 75° C i 18 timer, Reaksjonsblandingen inndampes under nedsatt trykk og oppvarmes med Alternatively, a solution of 568 mg (8 milliequivalents) is heated. poly-((methylimino)-trimethylene) and 6.3 g (40 mmol) of l-bromo-3-chloropropane in 20 ml of dimethylformamide at 75° C. for 18 hours. The reaction mixture is evaporated under reduced pressure and heated with
30 ml flytende ammoniakk ved 50° C i 5 timer. Ammoniakken får lov 30 ml of liquid ammonia at 50° C for 5 hours. Ammonia is allowed
til å fordampe, og produktet overføres til den'kloridion-holdige form ved å føre det gjennom en 45 ml kolonne med "Dowex 1-X2" ionebytteharpiks i kloridformen. • to evaporate, and the product is transferred to the chloride ion-containing form by passing it through a 45 ml column of "Dowex 1-X2" ion exchange resin in the chloride form. •
For syntesen av polymerer med formel III hvor R-^og R2er henholdsvis 3-ammoniopropyl og methyl i forhold varierende fra 5:95 til 95:5, er fremgangsmåten i det vesentlige som beskrevet ovenfor hvor poly (methylimino)-trimethylen omsettes med en begrensende mengde av enten 3-fthalimidopropylbromid eller l-brom-3-kl.orprepan, og derpå med et overskudd av methylbromid. For the synthesis of polymers of formula III where R-^ and R2 are respectively 3-ammoniopropyl and methyl in ratios varying from 5:95 to 95:5, the procedure is essentially as described above where poly(methylimino)-trimethylene is reacted with a limiting amount of either 3-phthalimidopropyl bromide or 1-bromo-3-chloroprepane, and then with an excess of methyl bromide.
Eksempel 35 Poly-({ methyl-( 3- methylammoniopropyl)- imino}- trimethylen- diklorid) Example 35 Poly-({methyl-(3-methylammoniopropyl)-imino}-trimethylene dichloride)
En oppløsning av 710 mg (10 milliekvivalenter) poly-((methylimino)-trimethylen} og 8 g l-brom-3-klorpropan i 30 ml dimethylformamid oppvarmes ved 75° C i 16 timer. Blandingen inndampes under nedsatt trykk, suspenderes i 10 ml methanol og behandles med 3 g methylamin ved 50° C i et forseglet rør. Reaksjonsblandingen inndampes under nedsatt trykk, taes opp i vann og føres gjennom en 50. ml kolonne med "Dowex 1-X2" ionebytteharpiks for å få det ønskede produkt. A solution of 710 mg (10 milliequivalents) of poly-((methylimino)-trimethylene} and 8 g of 1-bromo-3-chloropropane in 30 ml of dimethylformamide is heated at 75° C. for 16 hours. The mixture is evaporated under reduced pressure, suspended for 10 ml of methanol and treated with 3 g of methylamine at 50° C in a sealed tube. The reaction mixture is evaporated under reduced pressure, taken up in water and passed through a 50 ml column with "Dowex 1-X2" ion exchange resin to obtain the desired product.
For syntesen av polymeren med formel III hvor R-j_ og R2er henholdsvis 3-methylammoniopropyl og methyl i forhold varierende fra 5:95 til 95:5, er fremgangsmåten i det vesentlige den samme som beskrevet ovenfor hvor poly-((methylimino)-trimethylen)- først omsettes .med en begrensende mengde l-brom-3-klorpropan og derpå med et overskudd av methylbromid. For the synthesis of the polymer of formula III where R-j_ and R2 are respectively 3-methylammoniopropyl and methyl in ratios varying from 5:95 to 95:5, the procedure is essentially the same as described above where poly-((methylimino)-trimethylene )- is first reacted with a limiting amount of 1-bromo-3-chloropropane and then with an excess of methyl bromide.
Eksempel 36. Example 36.
P o ly- ({met.iiy.t~( 3-' d . ime t hyl ' ammohiopr opy 1) - imi no} tr' ime thy 1 en - d i k 1 or i d) P o ly- ({met.iiy.t~( 3-' d . ime t hyl ' ammohiopr opy 1) - imi no} tr' ime thy 1 en - d i k 1 or i d)
En oppløsning av 710 mg (10. milliekvivalenter) poly-((methylimino).-trimethylen}- og 7,9- g l-brom-3-klorpropan i 35 ml dimethylf ormamid oppvarmes ved 7 5° C i 16' timer. Blandingen inndampes under nedsatt trykk, suspenderes i 10 ml methanol og behandles med 2,3 g (50 mmol) dimethylamin ved 50° C i et forseglet rør. Reaksjonsblandingen inndampes under nedsatt trykk, taes opp i vann og føres gjennom en 50 ml kolonne med "Dowex 1-X2" ionebytteharpiks (40 mmol klorion) hvilket gir poly-({methyl-(3-dimethylammoniopropyl)-imino}-trimethylen-diklorid}. A solution of 710 mg (10 milliequivalents) of poly-((methylimino).-trimethylene} and 7.9 g of 1-bromo-3-chloropropane in 35 ml of dimethylformamide is heated at 75° C. for 16 hours. The mixture is evaporated under reduced pressure, suspended in 10 ml of methanol and treated with 2.3 g (50 mmol) of dimethylamine in a sealed tube at 50° C. The reaction mixture is evaporated under reduced pressure, taken up in water and passed through a 50 ml column with "Dowex 1-X2" ion exchange resin (40 mmol chlorine ion) which gives poly-({methyl-(3-dimethylammoniopropyl)-imino}-trimethylene dichloride}.
Alternativt behandles en oppløsning av 710 mg (10 milliekvivalenter) poly-((methylimino)-trimethylen) i 35 ml dimethylformamid med 6,6 g (40 mmol) 3-dimethylaminopropylbromid ved 50° C i 6 timer. Produktet isoleres ved filtrering, taes opp i vann og føres gjennom en 5 0 ml kolonne med "Dov/ex 1-X2" ionebytteharpiks (40 mmol kloridion) hvilket gir 3-dimethylammoniopropyl-analogen ovenfor Alternatively, a solution of 710 mg (10 milliequivalents) of poly-((methylimino)-trimethylene) in 35 ml of dimethylformamide is treated with 6.6 g (40 mmol) of 3-dimethylaminopropyl bromide at 50° C. for 6 hours. The product is isolated by filtration, taken up in water and passed through a 50 ml column of "Dov/ex 1-X2" ion exchange resin (40 mmol chloride ion) which gives the 3-dimethylammoniopropyl analogue above
For syntesen av polymere med formel III hvor R-^og R2er henholdsvis 3-dimethylammoniopropyl og methyl i forhold varierende fra 5:95 til 95:5, er fremgangsmåten i det vesentlige som beskrevet ovenfor hvor poly-((methylimino)-trimethylen) behandles med enten en begrensende mengde l-brom--3-klorpropan eller 3-dimethylaminopropylbromid, og derpå med et overskudd av methylbromid. For the synthesis of polymers of formula III where R-^ and R2 are respectively 3-dimethylammoniopropyl and methyl in ratios varying from 5:95 to 95:5, the procedure is essentially as described above where poly-((methylimino)-trimethylene) is treated with either a limiting amount of 1-bromo-3-chloropropane or 3-dimethylaminopropyl bromide, and then with an excess of methyl bromide.
Eksempel 37 Example 37
Poly- ({ methyl- ( 3- trimethylammoniopropyl) -i mino}- trimethylen- dibromid) Poly-({methyl-(3-trimethylammoniopropyl)-imino}-trimethylene-dibromide)
En oppløsning av 710 mg (10 milliekvivalenter) poly-((methylimino)-trimethylen} og 10,4 g (40 mmol) 3-brompropyltri-methylammoniumbromid i 40 ml renset dimethylformamid oppvarmes ved 75° C i 12 timer. Produktet isoleres ved filtrering, vaskes med aceton og tørres under nedsatt trykk hvilket gir 1,8 g poly-({methyl-( 3-tr.imethylammoniopropyl) -imino}-tr ime thy len-dibromid)- . A solution of 710 mg (10 milliequivalents) of poly-((methylimino)-trimethylene} and 10.4 g (40 mmol) of 3-bromopropyltrimethylammonium bromide in 40 ml of purified dimethylformamide is heated at 75° C. for 12 hours. The product is isolated by filtration , washed with acetone and dried under reduced pressure, which gives 1.8 g of poly-({methyl-(3-trimethylammoniopropyl)-imino}-tri ime thylene dibromide)- .
Eksempel 38 Example 38
Poly- ({ methyl-( 3- t- rimethylammoniopropyl) - imino)- trimethylen- dibromid] Poly-({methyl-(3-trimethylammoniopropyl)-imino)- trimethylene dibromide]
En oppløsning av 1,66 g (5 milliekviv.) poly-({methyl-(3-trimethyiammoniopropyl)-imino}-trimethylen-dibromid) i 85 ml vann føres langsomt gjennom en kolonne inneholdende 50 ml (40 mmol) "Dowex I-X 2." harpiks i kloridion-formen. : Vann føres så gjennom inntil intet kloridion kan påvises i eluatet. Inndampning av det forenede, eluat .til tørrhet ved 50°. C gir. 1,1 g poly-({methyl-(3-trimethylammoniopropy1 l-imino}-trimethylen-diklorid). A solution of 1.66 g (5 milliequiv.) of poly-({methyl-(3-trimethylammoniopropyl)-imino}-trimethylene dibromide) in 85 ml of water is passed slowly through a column containing 50 ml (40 mmol) of "Dowex I-X 2." resin in the chloride ion form. : Water is then passed through until no chloride ion can be detected in the eluate. Evaporation of the combined eluate to dryness at 50°. C provides. 1.1 g of poly-({methyl-(3-trimethylammoniopropyl 1-imino}-trimethylene dichloride).
For syntesen av polymerer med formel III hvor og R2er henholdsvis-' 3-trimethylammoni.opropyl og methyl i forhold varierende fra 5:9.5 til 9.5:5, er syntesen i. det vesentlige som beskrevet ovenfor i, eksempel 37 hvor ' poly-{-(methylimino)-trimethylen} omsettes med en begrensende, mengde 3-brompropyltrirnethylamKioniumbromid og derpå med et overskudd av methylbromid.. For the synthesis of polymers of formula III where and R2 are respectively -' 3-trimethylammoni.opropyl and methyl in ratios varying from 5:9.5 to 9.5:5, the synthesis i. is essentially as described above in, example 37 where ' poly- -(methylimino)-trimethylene} is reacted with a limiting amount of 3-bromopropyltrimnethylammonium bromide and then with an excess of methyl bromide.
Eksempel 39 Example 39
Poly- ({meth yl-( carboethoxymethyl) - imino}- trimethylen- klori. d) Poly-({meth yl-(carboethoxymethyl)-imino}-trimethylene- chloride. d)
En oppløsning av 1 g (14 milliekviv.) poly-((methylimino)-trimethylen) og 8,8"g (56 mmol) ethyl-a-bromacetat i 20 ml dimethylformamid oppvarmes ved 50° C i 12 timer. Blandingen fortynnes med fem volum ether og produktet isoleres for filtrering. Produktet taes-opp i vann og føres gjennom en 7 5 ml kolonne med "Dowex 1-X2" ionebytteharpiks .(SO mmol kloridion) og eluatet inndampes under nedsatt trykk hvorved man får poly-({methyl-(carboethoxymethyl)-imino}-trimethylen-klorid) . A solution of 1 g (14 milliequiv.) poly-((methylimino)-trimethylene) and 8.8 g (56 mmol) ethyl-a-bromoacetate in 20 ml of dimethylformamide is heated at 50° C. for 12 hours. The mixture is diluted with five volumes of ether and the product is isolated for filtration. The product is taken up in water and passed through a 7 5 ml column with "Dowex 1-X2" ion exchange resin (SO mmol chloride ion) and the eluate is evaporated under reduced pressure whereby poly-({ methyl-(carboethoxymethyl)-imino}-trimethylene chloride) .
Eksempel 40 Example 40
Poly-({ methyl-( ca. rbor. y latomethy 1)- imino}- trimethylen) Poly-({ methyl-( c. rbor. y latomethy 1)- imino}- trimethylene)
En oppløsning av 500 mg (7 milliekviv.) poly-((methylimino)-trimethylen} og 4,4 g (28 mmol) ethyl-a-bromacetat i 10 ml renset dimethylformamid oppvarmes ved 50° C i 12 timer.. Reaksjonsblandingen inndampes til tørrhet under nedsatt trykk, og residuet behandles med 28 ml IN natriumhydroxyd over natten. Deretter tilsettes 21 ml IN saltsyre til blandingen og oppløsningen avsaltes i en "Amicon",filtercelle forsynt med et "UM2 Diaflo Ultrafilter". Oppløsningen inndampes til tørrhet ved 50° C hvilket gir 650 mg poly- ({methyl- (carboxylatomethyl)*-imino}-trimethylen) . A solution of 500 mg (7 milliequiv.) poly-((methylimino)-trimethylene} and 4.4 g (28 mmol) ethyl-α-bromoacetate in 10 ml purified dimethylformamide is heated at 50° C. for 12 hours. The reaction mixture is evaporated to dryness under reduced pressure, and the residue is treated with 28 ml 1N sodium hydroxide overnight. Then 21 ml 1N hydrochloric acid is added to the mixture and the solution is desalted in an "Amicon", filter cell equipped with a "UM2 Diaflo Ultrafilter". The solution is evaporated to dryness at 50 ° C which gives 650 mg of poly-({methyl-(carboxylatomethyl)*-imino}-trimethylene).
For syntesen av polymeren med formel III hvor R^og R2er henholdsvis carboxylatomethyl'og methyl i forhold varierende fra 5:95 til 95:5, er fremgangsmåten i det vesentlige som beskrevet ovenfor hvor poly-((methylimino)-trimethylen) omsettes med en begrensende mengde eth.yl-a-bromacetat og derpå med et overskudd av methylbromid. For the synthesis of the polymer of formula III where R 1 and R 2 are respectively carboxylatomethyl and methyl in ratios varying from 5:95 to 95:5, the procedure is essentially as described above where poly-((methylimino)-trimethylene) is reacted with a limiting amount of ethyl-α-bromoacetate and then with an excess of methyl bromide.
Eksempel 41. ,, ..... Example 41. ,, .....
Pqly-'( {roe thyl-( carb Pqly-'( {roe thyl-( carb
En. oppløsning av 355 mg (5 .milliekvivalenter) poly-((methylimino 1-trimethylen}- og 3,5 g (25 mmol) .2-bromacetamid i. 10 ml dimethylformamid oppvarmes ved 60°.C 1 15 timer. Produktet isoleres ved filtrering, taes opp,i vann og-føres gjennom en 25 ml'kolonne med "B.owex 1-X2" ionebytteharpiks (20 mmol kloridion) hvilket gir poly-({methyl-(carbamylmethyl)-imino}-trimethylen-klorid) . One. solution of 355 mg (5 milliequivalents) of poly-((methylimino 1-trimethylene) and 3.5 g (25 mmol) of 2-bromoacetamide in 10 ml of dimethylformamide is heated at 60°C for 15 hours. The product is isolated at filtration, taken up in water and passed through a 25 ml column with "B.owex 1-X2" ion exchange resin (20 mmol chloride ion) which gives poly-({methyl-(carbamylmethyl)-imino}-trimethylene chloride) .
For polymerer med formel III hvor R-^og R2er henholdsvis carbamylmethyl og methyl i forhold varierende fra 95:5 til 5:95, For polymers of formula III where R-^ and R2 are respectively carbamylmethyl and methyl in ratios varying from 95:5 to 5:95,
er fremgangsmåten i det vesentlige som beskrevet ovenfor hvor poly-((methylimino)-trimethylen} behandles først med en begrensende mengde 2-bromacdtamid og derpå med et overskudd av methylbromid. is the process essentially as described above where poly-((methylimino)-trimethylene} is first treated with a limiting amount of 2-bromoacetamide and then with an excess of methyl bromide.
Eksempel 4 2 Example 4 2
Poly-{{methyl-(3-N^-methylcarbamidinopropyl)-imino}-trimethylen-• klorid- hydroklorid) ' Poly-{{methyl-(3-N^-methylcarbamidinopropyl)-imino}-trimethylene-• chloride- hydrochloride) '
En oppløsning av 719 mg (10 milliekvivalenter) poly ((methylimino)-trimethylen)- og 12,5 g (40 mmol) 4-brom-N<2->methy.l-N-benzyloxycarbonylbutyramidin i 50 ml dimethylformamid oppvarmes ved 75° C i 16 timer. Blandingen inndampes under nedsatt trykk og produktet ekstraheres i vann. Den vandige oppløsning syres til pH 3 med saltsyre, hydrogeneres over en 5 %-ig Pd/carbonkatalysator, filtreres og førs gjennom en 100 ml kolonne med "Dowex 1-X2" ionebytteharpiks (80 mmol kloridion) hvilket gir det ønskede produkt inneholdende klorid-motionet. A solution of 719 mg (10 milliequivalents) of poly((methylimino)-trimethylene)- and 12.5 g (40 mmol) of 4-bromo-N<2->methyl.1-N-benzyloxycarbonylbutyramide in 50 ml of dimethylformamide is heated at 75° C. for 16 hours. The mixture is evaporated under reduced pressure and the product is extracted in water. The aqueous solution is acidified to pH 3 with hydrochloric acid, hydrogenated over a 5% Pd/carbon catalyst, filtered and passed through a 100 ml column with "Dowex 1-X2" ion exchange resin (80 mmol chloride ion), which gives the desired product containing chloride- the motion.
For forbindelser med formel III hvor R^og Rp er henholdsvis 3-N 2-methylcarbamidinopropyl og methyl i forhold på 95:5 til 5:95, anvendes den ovenfor beskrevne metode hvor poly-((methylimino)-trimethylen)- først behandles med en begrensende mengde 4-brom-N^-methyl-N-benzyloxycarbonylbutyryamidin og derpå med et overskudd av methylbromid. For compounds of formula III where R^ and Rp are respectively 3-N 2-methylcarbamidinopropyl and methyl in a ratio of 95:5 to 5:95, the method described above is used where poly-((methylimino)-trimethylene)- is first treated with a limiting amount of 4-bromo-N^-methyl-N-benzyloxycarbonylbutyryamidine and then with an excess of methyl bromide.
Eksempel 4 3 Example 4 3
Poly-({methyl-(3-guanidinopropyl)-imino}-trimethylen-klorid-hydrokloridj '.. ' ' Poly-({methyl-(3-guanidinopropyl)-imino}-trimethylene chloride hydrochloridej '.. ' '
En oppløsning av 355 mg (5 milliekvivlaneter) poly-((methylimino)-trimethylen)- og 5,6 g (25 mmol)N^-3-brompropyl-N<3->ni.troguanidl.n . i 15 ml dimethylf ormamid oppvarmes ved 75° C i 16 timer. Blandingen inndampes under nedsatt trykk og produktet ekstraheres- i. vann. Den vandige oppløsning syres til pH 3 med saltsyre og hydrogeneres i nærvær .av 100- mg aktivert-platina. Oppløsningen filtreres og føres gjennom en 50 ml kolonne med "Dpwex 1- X2" ionebytteharpiks (40 mmol kloridion) .hvilket- gir. det .ønskede produkt inneholdende, klorld-motionet. A solution of 355 mg (5 milliequivalents) of poly-((methylimino)-trimethylene)- and 5.6 g (25 mmol) of N^-3-bromopropyl-N<3->ni.troguanidyl.n . in 15 ml of dimethylformamide is heated at 75° C. for 16 hours. The mixture is evaporated under reduced pressure and the product is extracted in water. The aqueous solution is acidified to pH 3 with hydrochloric acid and hydrogenated in the presence of 100 mg of activated platinum. The solution is filtered and passed through a 50 ml column of "Dpwex 1-X2" ion exchange resin (40 mmol chloride ion), which gives the .desired product containing, the chloride motion.
Forbindelser med formel III hvor R-^ og R2er henholdsvis-3-guani.dinopropyl og methyl i. forhold varierende fra 95:5 til 5:95, anvendes den ovenfor beskrevne fremgangsmåte hvor poly- (methylimino). -trimethylen først behandles med en begrensende mengde N^-3-brompropyl-N 3 -nitroguanidin og derpå o med et overskudd av methylbromid. Compounds of formula III where R-1 and R2 are respectively -3-guanidinopropyl and methyl in ratios varying from 95:5 to 5:95, the method described above is used where poly-(methylimino). -trimethylene is first treated with a limiting amount of N^-3-bromopropyl-N 3 -nitroguanidine and then o with an excess of methyl bromide.
Ek.s.ejnp. tf,1,.,,. 4 4 Ek.s.ejnp tf,1,.,,. 4 4
Poly- f{ methyl-( 2- oxopropyl)- imino}- trimethylen- klorid) Poly-f{methyl-(2-oxopropyl)-imino}-trimethylene- chloride)
En oppløsning av 355 mg (5 milliekvivalenter) poly-((methylimino).-trimethylen} og 2,3 g (25 mmol) klorpropanon-2'opp-yarmes ved 50° C i. 16 timer. Produktet isoleres ved filtrering, tritureres med ether og tørres under nedsatt trykk. A solution of 355 mg (5 milliequivalents) of poly-((methylimino).-trimethylene} and 2.3 g (25 mmol) of chloropropanone-2' is heated at 50° C. for 16 hours. The product is isolated by filtration, triturated with ether and dried under reduced pressure.
For polymerer av formel III hvor R-^og R2er henholdsvis 2-oxopropyl og methyl i'.'forhold varierende fra 95:5 til 5:95, følges den ovenfor beskrevne fremgangsmåte hvor poly-((methylimino)-trimethylen) først behandles med en begrensende mengde klorpropanon-2 og derpå med et overskudd av methylbromid. Behandling av produktet med "Dowex 1- X2" i klorid-formen gir produktet inneholdende bare kloridionet. For polymers of formula III where R and R are respectively 2-oxopropyl and methyl in ratios varying from 95:5 to 5:95, the above-described procedure is followed where poly-((methylimino)-trimethylene) is first treated with a limiting amount of chloropropanone-2 and then with an excess of methyl bromide. Treatment of the product with "Dowex 1-X2" in the chloride form gives the product containing only the chloride ion.
. Eksempel 45 . Example 45
Poly- f { methyl- ( benzyl) - imino}- trimethylen- klorid) Poly-f{methyl-(benzyl)-imino}-trimethylene- chloride)
En oppløsning av 710 mg (IQ milliekvivalenter) poly-((methylimino)-trimethylen} og 6,8 g (40 mmol) benzylbromid i 15 ml dimethylformamid oppvarmes ved 50° C i 16 timer. Produktet isoleres ved inndampning av reaksjonsbalndingen under nedsatt trykk og ekstraksjon i vann. Den vandige oppløsning føres gjennom en 25 ml kolonne med "Dowex 1-X2" ionebytteharpiks (40 mmol kloridion) hvilket gir det ønskede produkt inneholdende klorid-motionet. A solution of 710 mg (IQ milliequivalents) of poly-((methylimino)-trimethylene} and 6.8 g (40 mmol) of benzyl bromide in 15 ml of dimethylformamide is heated at 50° C. for 16 hours. The product is isolated by evaporation of the reaction mixture under reduced pressure and extraction in water.The aqueous solution is passed through a 25 ml column of "Dowex 1-X2" ion exchange resin (40 mmol chloride ion) giving the desired product containing the chloride ion.
For polymerer med formel III hvor R-^og R2er henholdsvis benzyl og methyl, følges den ovenfor beskrevne fremgangsmåte hvor poly- (methylimino).-trimethylen først omsettes med en begrenset mengde, benzylbromid og derpå med et overskudd av methylbromid. For polymers of formula III where R and R are respectively benzyl and methyl, the method described above is followed where poly-(methylimino).-trimethylene is first reacted with a limited amount of benzyl bromide and then with an excess of methyl bromide.
Eksempel 4 6 Example 4 6
Poly-f{methyl-(l-propen-3- yl)- imino}- trimethylen- klorid) Poly-f{methyl-(1-propen-3-yl)-imino}-trimethylene- chloride)
En oppløsning av 426 mg (6 milliekvivalenter) poly-((methylimino)-trimethylen)- og 3,7 g (30 mmol) 3-brompropen-l (allylbromid) i 12 ml dimethylformamid oppvarmes ved 50° C i 16 timer. Produktet isoleres ved filtrering og oppløses i vann. Den vandige oppløsning føres gjennom en 4 0 ml kolonne med "Dowex 1--X2" ionebytteharpiks (32 mmol kloridion) og eluatet inndampes under nedsatt trykk.hvilket gir det ønskede produkt inneholdende klorid-motionet. A solution of 426 mg (6 milliequivalents) of poly-((methylimino)-trimethylene) and 3.7 g (30 mmol) of 3-bromopropene-1 (allyl bromide) in 12 ml of dimethylformamide is heated at 50° C. for 16 hours. The product is isolated by filtration and dissolved in water. The aqueous solution is passed through a 40 ml column with "Dowex 1--X2" ion exchange resin (32 mmol chloride ion) and the eluate is evaporated under reduced pressure, which gives the desired product containing the chloride ion.
For forbindelser med formel III hvor R-^og R2er henholdsvis l-propen-3-yl og methyl i forhold varierende fra 95:5 til 5:95, tilsvarer fremgangsmåten den ovenfor beskrevne hvor poly-((methylimino)-trimethylen) omsettes med en begrenset mengde 3-brompropen-l og derpå med et bverskudd av methylbromid. For compounds of formula III where R-^ and R2 are respectively 1-propen-3-yl and methyl in ratios varying from 95:5 to 5:95, the method corresponds to the one described above where poly-((methylimino)-trimethylene) is reacted with a limited amount of 3-bromopropene-1 and then with a shot of methyl bromide.
Eksempel 4 7 Example 4 7
Poly- f{ methyl-( l- propyn- 3- yl)- imino}- trimethylen- klorid) Poly-f{methyl-(l-propyn-3-yl)-imino}-trimethylene- chloride)
En oppløsning av 710 mg (10 milliekvivalenter) poly_ A solution of 710 mg (10 milliequivalents) of poly_
((methylimino)-trimethylen) og 3,6 g (30 mmol) 3-brompropyn-l (propargylbromid)'i 12 ml dimethylf ormamid oppvarmes ved 50° C i 16 timer. Produktet isoleres ved filtrering, oppløses i vann og føres gjennom en 4 0 ml kolonne med "Dowex 1-X2" ionebytteharpiks (32 mmol kloridion) hvilket gir det ønskede produkt inneholdende klorid-motionet. ((methylimino)-trimethylene) and 3.6 g (30 mmol) of 3-bromopropyn-1 (propargyl bromide) in 12 ml of dimethylformamide are heated at 50° C. for 16 hours. The product is isolated by filtration, dissolved in water and passed through a 40 ml column with "Dowex 1-X2" ion exchange resin (32 mmol chloride ion), which gives the desired product containing the chloride ion.
Som i de tidligere eksempler fremstilles polymerer med formel III hvor R-^er l-propyn-3-yl og R2er methyl i forhold varierende fra 5:95 til 95:5, ved først å behandle poly-((methylimino)-trxmethylenj med en begrenset msngde propargylbromid og derpå med et overskudd av methylbromid. As in the previous examples, polymers of formula III where R-1 is 1-propyn-3-yl and R2 is methyl in ratios varying from 5:95 to 95:5 are prepared by first treating poly-((methylimino)-trxmethylenej with a limited amount of propargyl bromide and then with an excess of methyl bromide.
Eksempel 48 Example 48
Poly- f{ methyl-( 2, 2, 2- trifluorethyl)- imino}- trimethylen- klorid) Poly- f{ methyl-( 2, 2, 2- trifluoroethyl)- imino}- trimethylene- chloride)
En oppløsning av 355 mg (5 milliekvivalenter) poly-((methylimino)-trimethylen) og 6,2 g (22 mmol) 2,2,2-trifluorethy1-triklormethylsulfonat i 15 ml dimethylformamid oppvarmes ved 50° C A solution of 355 mg (5 milliequivalents) of poly-((methylimino)-trimethylene) and 6.2 g (22 mmol) of 2,2,2-trifluoroethyl-trichloromethylsulfonate in 15 ml of dimethylformamide is heated at 50° C.
i 16 timer. Reaksjonsblandingen fortynnes med ether og produktet isoleres ved filtrering. Produktet taes opp i vann og føres gjennom en 25 ml kolonne med "Dowex 1-2" ionebytteharpiks (20 mmol kloridion) og eluatet inndampes under nedsatt trykk hvilket gir det for 16 hours. The reaction mixture is diluted with ether and the product is isolated by filtration. The product is taken up in water and passed through a 25 ml column with "Dowex 1-2" ion exchange resin (20 mmol chloride ion) and the eluate is evaporated under reduced pressure which gives
ønskede produkt inneholdende klorid-motionet. desired product containing the chloride motion.
For polymerer med formel III hvor Rj er 2, 2,2-trifluor-ethy 1 og R2er methyl i forhold varierende fra 95:5 til 5:95, anvendes de ovenfor beskrevne metoder hvor poly-((methylimino)-trimethylen} først behandles med en begrenset mengde 2,2,2-trifluor-ethyl-triklormethylsulfonat og derpå med et overskudd av methylbromid . For polymers of formula III where Rj is 2,2,2-trifluoroethyl 1 and R2 is methyl in ratios varying from 95:5 to 5:95, the methods described above are used where poly-((methylimino)-trimethylene} is first treated with a limited amount of 2,2,2-trifluoroethyl-trichloromethylsulfonate and then with an excess of methyl bromide.
Eksempel 4 9 Example 4 9
Poly-({meth yl-( 1- - p- glucopyranosy1)- imino}- trimethyle n- klorid) Poly-({meth yl-( 1- - p- glucopyranosyl)-imino}-trimethylen- chloride)
En oppløsning av 535 mg (5 milliekvivalenter) poly-((methylimino)-trimethylen} og 10,3 g (25 mmol) tetra-0-acetyl--ct-D-glucopyranosylbromid i 25 ml dimethylformamid oppvarmes ved 50° C A solution of 535 mg (5 milliequivalents) of poly-((methylimino)-trimethylene} and 10.3 g (25 mmol) of tetra-O-acetyl--ct-D-glucopyranosyl bromide in 25 ml of dimethylformamide is heated at 50° C.
i 16 timer. Produktet isoleres ved fortynning med ether fulgt av filtrering. Produktet taes opp i 5 ml vann og 2 ml 10 %-ig hydro-genbromid tilsettes. Etter henstand over natten fortynnes oppløs-ningen til et volum på 100 ml med vann og anbringes i en "Amicon" filtercelle inneholdende et "UM-2 DiafloUltrafilter". Etter at 800 ml filtrat er oppsamlet, inndampes det gjenholdte til 'et volum på 50 ml og føres gjennom en 25 ml kolonne med "Dov/ex 1-X2" ione- "■ ^ bytteharpiks' (20 mmol kloridion). Inndampning av eluatet gir den ønskede analog inneholdende klorid-motionet. for 16 hours. The product is isolated by dilution with ether followed by filtration. The product is taken up in 5 ml of water and 2 ml of 10% hydrogen bromide is added. After standing overnight, the solution is diluted to a volume of 100 ml with water and placed in an "Amicon" filter cell containing a "UM-2 DiafloUltrafilter". After 800 ml of filtrate has been collected, the residue is evaporated to a volume of 50 ml and passed through a 25 ml column of "Dov/ex 1-X2" ion exchange resin (20 mmol chloride ion). Evaporation of the eluate gives the desired analogue containing the chloride moiety.
For forbindelser med formel III hvor R-^er 1-a-D-glucj-pyranosyl og R2er methyl i forhold varierende fra 95:5 til 5:95, følges den ovenfor beskrevne metode hvor poly- [(methylimino)-tri-methylenj behandles først med en begrenset mengde tetra-O-acetyl-a-D-glucopyranosylbromid og derpå med et overskudd av methylbromid. For compounds of formula III where R-^ is 1-a-D-glucj-pyranosyl and R2 is methyl in ratios varying from 95:5 to 5:95, the method described above is followed where poly-[(methylimino)-tri-methylenej is treated first with a limited amount of tetra-O-acetyl-α-D-glucopyranosyl bromide and then with an excess of methyl bromide.
Fremgangsmåtene beskrevet i eksempler 27 ,til 49 er like anvendbare for overføringer av poly-((methylimino)-ethylen} til de tilsvarende kvartære analoger og følger under anvendelse av de tilsvarende milliekvivalenter av poly-^(methylimino)-triethylenj isteden for poly-((methylimino)-trimethylen) som vist i eksempel 50. The procedures described in Examples 27 to 49 are equally applicable to transfers of poly-((methylimino)-ethylene} to the corresponding quaternary analogues and follow using the corresponding milliequivalents of poly-^(methylimino)-triethylenej instead of poly-( (methylimino)trimethylene) as shown in Example 50.
Eksem pel 5 0 Example pel 5 0
Poly-({ methyl-( 2- trimethylammonioethyl)- imino}- ethylen- dibromid) Poly-({ methyl-( 2- trimethylammonioethyl)- imino}- ethylene dibromide)
En oppløsning av 570 mg (10 miiliekvivlanter) poly-((methylimino)-ethylen)- og 9,9 g (40 mmol) 2-bromethyltrimethyl-ammoniumbromid i 40 ml dimethylformamid oppvarmes ved 7 5° C i 12 timer. Etter avkjøling fortynnes reaksjonsblandingen med fem volum ether, og produktet isoleres ved filtrering og tørres under nedsatt trykk. A solution of 570 mg (10 milliequivalents) of poly-((methylimino)ethylene) and 9.9 g (40 mmol) of 2-bromomethyltrimethylammonium bromide in 40 ml of dimethylformamide is heated at 75° C. for 12 hours. After cooling, the reaction mixture is diluted with five volumes of ether, and the product is isolated by filtration and dried under reduced pressure.
Effektiv senkning av cholesterolblodspeil fåes ved oral administrasjon av bemerkelsesverdige små doser av polymerene som fremtilles ifølge oppfinnelsen. Dette muliggjør en fleksibilitet Effective lowering of cholesterol blood levels is obtained by oral administration of remarkably small doses of the polymers produced according to the invention. This enables flexibility
i fremstilling av preparatet som tidligere ikke var mulig. Polymerene kan være findelte pulvere og kan passende anvendes som sådan-ne eller fortrinnsvis blandet med forskjellige mengder av faste bærere som kolloidal kiselsyre, stivelser, sucrose, talkum, lactose, cellulose eller modifisert cellulose, tørrmelkpulver, proteinpulvere som soyamel og lignende. De oppgjøres vanligvis i enhetsdose-former som tabletter, fylte gelatinkapsler eller en blikk- eller papirkonvolutt inneholdende den forut målte dose som kan innbefatte supplerende vitaminer og mineraler, og som lett kan rives åpen og tilsettes tii spiselige væsker som fruktsafter eller andre drikker. Enhetsdosepreparatet kan omfatte fra 10 til 9 9 vekt% polymer, idet det gjenværende er bærere, smaksstoffer, eksipienter, rislingsmid-ler og lignende. I en slik "enhetsdose kan den aktive^polymer ut-gjøre fra 0,1 g til opp til 10 g i pulverpakker. in the preparation of the preparation which was previously not possible. The polymers can be finely divided powders and can suitably be used as such or preferably mixed with different amounts of solid carriers such as colloidal silicic acid, starches, sucrose, talc, lactose, cellulose or modified cellulose, dry milk powder, protein powders such as soy flour and the like. They are usually provided in unit dose forms such as tablets, filled gelatin capsules or a tin or paper envelope containing the pre-measured dose which may include supplementary vitamins and minerals, and which can be easily torn open and added to edible liquids such as fruit juices or other drinks. The unit dose preparation may comprise from 10 to 99% by weight of polymer, the remainder being carriers, flavourings, excipients, wetting agents and the like. In such a unit dose, the active polymer can amount from 0.1 g to up to 10 g in powder packets.
Også egnet er vandige oppløsninger eller suspensjoner som kan fremstilles og som fortrinnsvis tilsettes søtemiddel eller smaksstoff. Skjønt det ikke er heit ønskelig, kan polymerene blandes med forskjellige medier som safflor- eller maisolje for oral inntagelse som sådan eller som en vandig emulsjon. Disse kan også innkapsles. Also suitable are aqueous solutions or suspensions that can be prepared and to which a sweetener or flavoring agent is preferably added. Although not highly desirable, the polymers can be mixed with various media such as safflower or corn oil for oral administration as such or as an aqueous emulsion. These can also be encapsulated.
Som ovenfor nevnt oppdeles fortrinnsvis den samlede dagsdose av gallesyrebindende polymer i porsjoner og taes før hvert måltid eller før sengetid. Denne administreringsrutine gir maksi-mal harpikskbntakttid under perioder med høyeste intestinale galle-syrekonsentrasjoner. As mentioned above, the total daily dose of bile acid-binding polymer is preferably divided into portions and taken before each meal or before bedtime. This administration routine provides maximum resin contact time during periods of highest intestinal bile acid concentrations.
Polymerene ifølge oppfinnelsen kan anvendes alene, eller, om ønskes, kan de opparbeides sammen med triglyceridsynteseinhibi-torer eller andre gallesyrebindende midler for særlige behandlinger. Dessuten danner, som nevnt ovenfor, de her beskrevne spolymerer salter med syrer av clofibrat og halofenat, hvilke salter er nyttige i cardiovasculær sykdomsterapi. De følgende eksempler illustre-rer doseformene som kan anvendes ved utførelse av oppfinnelsen. Fagfolk i fremstilling av farmasøytiske preparater vil være opp-merksom på variasjoner som kan utføres uten å avvike fra oppfinnelsen. Det forutsees at multiple doser, f.eks. to eller tre tablet ter eller kapsler, .kan taes på en gang hvis høyere doser er fore-skrevet. The polymers according to the invention can be used alone, or, if desired, they can be processed together with triglyceride synthesis inhibitors or other bile acid binding agents for special treatments. Moreover, as mentioned above, the spolymers described here form salts with acids of clofibrate and halofenate, which salts are useful in cardiovascular disease therapy. The following examples illustrate the dosage forms that can be used in carrying out the invention. Professionals in the manufacture of pharmaceutical preparations will be aware of variations that can be made without deviating from the invention. It is anticipated that multiple doses, e.g. two or three tablets or capsules can be taken at once if higher doses are prescribed.
Ytterligere bestanddeler som kan omfatte bærerdelen av Additional ingredients that may include the carrier portion of
■preparatene'ifølge oppfinnelsen, kan også ha farmakologisk aktivi-tet og kan innbefatte andre choleretiske midler som tocamfyl-florantyron; taurin; og glycin; hypocholesteremiske midler som nicotinsyre; D-isomeren av 3,3',5-trijodthyronin; thyroxin-lignende forbindelser som natrium-L-thyroxin og natrium-D-thyroxin ; trijod-thyropropionsyre?naf oxidin-hydroklori.1, 5-methylpyrazol-3-carboxyl-syre og 3-methyl-5-isoxazolcarboxylsyre; fecalmyknere som poloxalkol og dioctyl-natrium-suifosuccinat; såvel som umettede fettsyrer som linolsyre, arachidonsyre og linolensyre; spiselige vegetabilske, syrer som maisolje og safflovolje. ■the preparations' according to the invention may also have pharmacological activity and may include other choleretic agents such as tocamfyl-florantyrone; taurine; and glycine; hypocholesteremic agents such as nicotinic acid; The D-isomer of 3,3',5-triiodothyronine; thyroxine-like compounds such as sodium-L-thyroxine and sodium-D-thyroxine; triiodo-thyropropionic acid?naf oxidine hydrochloride.1, 5-methylpyrazole-3-carboxylic acid and 3-methyl-5-isoxazolecarboxylic acid; fecal softeners such as poloxalcol and dioctyl sodium suifosuccinate; as well as unsaturated fatty acids such as linoleic acid, arachidonic acid and linolenic acid; edible vegetable, acids such as corn oil and safflower oil.
Pulverpakker Powder packs
Lineært, uforgrenet og ikke-tverrbundet poly-((dimethylimino). -ethylen-klorid)- med molvekt på ca. 20 000 finpulveriseres Linear, unbranched and non-crosslinked poly-((dimethylimino). -ethylene chloride)- with a molecular weight of approx. 20,000 are finely pulverized
og blandes med 1 vekt% lactosepulver. Aluminiumkonvolutter inneholdende en papirposetoring fylles individuelt med 0,55 g av blandingen og forsegles mot fuktighet for å forhindre kakning. and mixed with 1% by weight of lactose powder. Aluminum envelopes containing a paper bag ring are individually filled with 0.55 g of the mixture and sealed against moisture to prevent caking.
Istedenfor poly-((dimethylimino)-ethylenklorid) kan der anvendes, poly-(( 2-hydroxyethyl)-methyliminoethylenklorid)- eller andre polymerer ifølge- 'oppfinnelsen, med varierende molekylvekter fra ca. 1500" til ca.' 50 000 og høyere, og omfattende polymerer med en enkelt gjennomsnitts molekylvekt eller blandinger av forskjellige molekylvekter, så lenge som den i alminnelighet er over ca. 1500. Instead of poly-((dimethylimino)-ethylene chloride), poly-((2-hydroxyethyl)-methyliminoethylene chloride) or other polymers according to the invention, with varying molecular weights from approx. 1500" to approx.' 50,000 and above, and includes polymers of a single average molecular weight or mixtures of different molecular weights, as long as it is generally above about 1,500.
Hårde gelatinkapsler Hard gelatin capsules
Den samme dose, dvs. 0,55 g poly-((dimethylimino)-ethylen-klorid) inneholdende 1 vekt% lactose som beskrevet ovenfor, fylles i den passende størrelse hårde gelatinkapsler. The same dose, i.e. 0.55 g of poly-((dimethylimino)-ethylene chloride) containing 1% by weight of lactose as described above, is filled into the appropriate size hard gelatin capsules.
Alternativt kan en tørrfyllt kapsel fremstilles fra føl-gende bestanddeler: Alternatively, a dry-filled capsule can be made from the following ingredients:
Tørrfyllte kapsler kan likeledes fremstilles under anvendelse av en hvilken som helst av de andre nye polymerer angitt ovenfor. Hvis kapsler med lavere styrke fremstilles, kan kapselstyrken minskes eller ytterligere maisstivelse eller annet fortynningsmid-del anvendes. Ved anvendelse av mindre mengder aktiv bestanddel forutsees det at en dose av flere kapsler kan administreres. Dry-filled capsules may likewise be prepared using any of the other novel polymers noted above. If lower strength capsules are produced, the capsule strength may be reduced or additional corn starch or other diluent may be used. When using smaller amounts of active ingredient, it is anticipated that a dose of several capsules can be administered.
Pressede tabletter Pressed tablets
En tørr blanding ble fremstilt av følgende bestanddeler: A dry mixture was prepared from the following ingredients:
4000 tabletter ble presset fra denne sats ved dirkkte presning idet hver tablett inneholdt 2 50 mg av den ionogene polymer. Likeledes fremstilles pressede tabletter slik at hver tablett inneholder: 4000 tablets were pressed from this batch by direct compression, each tablet containing 250 mg of the ionic polymer. Likewise, pressed tablets are produced so that each tablet contains:
Etter tablettering kan en plastfilm påføres på tablettene for å forsegle dem mot fuktighet på i og for seg kjent vis. After tableting, a plastic film can be applied to the tablets to seal them against moisture in a manner known per se.
Dessuten kan et enterisk belegg påføres, om ønskes. Et slikt belegg kan omfatte fett, fettsyrer, vokser og blandinger derav, shellac, ammoniert chellac, og cellulosesyrefthalater påføres ved i og for seg kjente metoder. In addition, an enteric coating can be applied, if desired. Such a coating may comprise fat, fatty acids, waxes and mixtures thereof, shellac, ammoniated shellac, and cellulose acid phthalates applied by methods known per se.
Istedenfor poly- J (dimethyl) -iminoethylenkloridj kan der anvendes en hvilken som helst av polymerene ifølge oppfinnelsen. Instead of poly-J (dimethyl)-iminoethylene chloride, any of the polymers according to the invention can be used.
AnSre bindemidler kan anvendes istedenfor sucrose som dextrose, lactose, methylcellulose, naturlig og syntetiske gummier, og lignende. Talkum kan erstatte kalsium- eller magnesiumstearatet. Other binders can be used instead of sucrose such as dextrose, lactose, methylcellulose, natural and synthetic gums, and the like. Talc can replace the calcium or magnesium stearate.
En rekke lett tilgjengelige ikke-toksiske anti-kaknings-midler kan anvendes istedenfor den kolloidale siliciumsyre. A number of readily available non-toxic anti-caking agents can be used in place of the colloidal silicic acid.
Andre smøremidler, fortynningsmidler, bindemidler, farve-stoff er, smaksmidler og desintegratorer kan anvendes som kjent under anvendelse av våt- eller tørrgranuleringsmetoder, direkte, presset, sprøytetørring og lignende. Other lubricants, diluents, binders, colorants, flavoring agents and disintegrators can be used as known using wet or dry granulation methods, direct, pressed, spray drying and the like.
Om ønskes kan en tyggbar tablett fremstilles fra fortrinnsvis mikroinnkapslede polymerpartikler ved tørrgranulering som følger: If desired, a chewable tablet can be prepared from preferably microencapsulated polymer particles by dry granulation as follows:
Polymerene ifølge oppfinnelsen er dessuten særlig nyttige i hele deres molekylvektområde når de anvendes som midler for f lok-k.ulering av kolloidale partikler i væsker som f. eks. ferskvann og kloakkvann. De kan også anvendes som retensjonshjelpemidler når de tilsettes til papirtilsetningsmaterialer under papirfremstilling. Videre er polymerene viktige som anti-bacterielle og anti-statiske midler og som sistnevnte kan de anvendes ved behandling av bomull, ull og syntetiske'fibre. Disse polymerer kan også anvendes som vevnads myknere og farvestoffer, særlig for å binde den anioniske type av farvestoffer. Dessuten kan de anvendes som viskositets-byggere såvelsom for å øke de bacterielle egenskaper hos ikke-ionogene og kationiske vaskemiddelpreparater, kosmetica, hårsprøyer og lignende anvendelser. Når polymerene ifølge oppfinnelsen anvendes slik, anvendes de i en like stor mengde og på analogt vis med konvensjonelt kjente materialer som anvendes til samme formål. The polymers according to the invention are also particularly useful throughout their molecular weight range when they are used as agents for flocculation of colloidal particles in liquids such as e.g. fresh water and sewage water. They can also be used as retention aids when they are added to paper additives during papermaking. Furthermore, the polymers are important as anti-bacterial and anti-static agents and, like the latter, they can be used in the treatment of cotton, wool and synthetic fibres. These polymers can also be used as fabric softeners and dyes, especially to bind the anionic type of dyes. Moreover, they can be used as viscosity builders as well as to increase the bacterial properties of non-ionic and cationic detergent preparations, cosmetics, hair sprays and similar applications. When the polymers according to the invention are used in this way, they are used in an equal amount and in an analogous manner to conventionally known materials that are used for the same purpose.
Når de anvendes som klarings- eller flokkuleringsmidler, oppløses eller dispergeres fortrinnsvis polymerene ifølge oppfinnelsen i et vandig medium og tilsettes til vannet som skal behandles, i en mengde fra 60 g til 240 g polymer pr. 1000 liter vann som skal behandles. When they are used as clarifying or flocculating agents, the polymers according to the invention are preferably dissolved or dispersed in an aqueous medium and added to the water to be treated, in an amount of from 60 g to 240 g of polymer per 1000 liters of water to be treated.
I alminnelighet har polymerene ifølge oppfinnelsen en molekylvekt fra 300 til 50 000 eller mere. Skjønt de er egnet for anvendelse som flokkuleringsmidler og lignende, er de polymerer som har molekylvekter under 15 0 0 ikke egnet som gallesyrebindings-midler, og slike polymermolekyler .kan skilles fra molekylene med høy vekt ved kjente metoder. In general, the polymers according to the invention have a molecular weight of from 300 to 50,000 or more. Although they are suitable for use as flocculating agents and the like, the polymers having molecular weights below 1500 are not suitable as bile acid binding agents, and such polymer molecules can be separated from the high weight molecules by known methods.
Disse polymerer administreres oralt i en effektiv galle-syrebindingsdose. For å snke blodserum-cholesterolspe.il er det i alminnelighet en enkel eller multippel dose på fra ca. 0,1 til 5,0 g,egnet, skjønt doser over 10 g kan gies hvor nødvendig. Slike doser er også effek.ti.ve til å lindre symptomer på pruritus biliaris. Administrasjon kan skje i en rekke former, som som en suspensjon, These polymers are administered orally in an effective bile acid binding dose. To lower the blood serum cholesterol level, it is generally a single or multiple dose of from approx. 0.1 to 5.0 g, suitable, although doses above 10 g may be given where necessary. Such doses are also effective in relieving symptoms of pruritus biliary. Administration can take place in a number of forms, such as as a suspension,
i en vandig oppløsning, som en tyggbar eller belagt tablett, eller i en kapsel, og kan fortsettes for en utstrakt behandling. I alminnelighet er medikasjon på en daglig basis med hver dagsdose tatt i. oppdelte porsjoner, fortrinnsvis med måltider. in an aqueous solution, as a chewable or coated tablet, or in a capsule, and can be continued for an extended treatment. In general, medication is on a daily basis with each daily dose taken in divided portions, preferably with meals.
For bekjempelse av hypercholesterolemia finnes den spesielle individuelle dose, i lys av variasjoner i metabolisme og diet, ved en forutgående bestemmelse og kontinuerlig felling av blodserumcholesterolspeilene. En moderat dose kan således anvendes til å begynne med, og økes inntil det ønskede blodserum-cholesterol-speil er oppnådd og opprettholdt. Som en begynnelsesdose, som går forut for en siik individuell avpasning, er fra 2,5 til 100 mg/kg legemsvekt pr. dag tilfredsstillende, To combat hypercholesterolemia, the special individual dose is found, in light of variations in metabolism and diet, by a prior determination and continuous measurement of blood serum cholesterol levels. A moderate dose can thus be used to begin with, and increased until the desired blood serum cholesterol level is achieved and maintained. As an initial dose, which precedes a healthy individual adaptation, from 2.5 to 100 mg/kg body weight per day satisfactory,
En fagmann vil innse at Rj , R2 r R3og R^ når de er ami.no-lavere-alkyl, lavere-alkylammonio-lavereålkyl, dilaverealkylammoniolaverealkyl, også kan være i form av det frie amin, nemlig amino-laverealkyl, laverealkylamino-laverealkyl og dilaverealkylamino-laverealkyl. A person skilled in the art will recognize that R 1 , R 2 , R 3 and R 3 when they are amino-no-lower-alkyl, lower-alkylammonio-lower-alkyl, di-lower-alkylammonio-lower-alkyl, can also be in the form of the free amine, namely amino-lower-alkyl, lower-alkylamino-lower-alkyl and diloweralkylamino-loweralkyl.
Claims (36)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36904273A | 1973-06-11 | 1973-06-11 | |
US46226374A | 1974-04-19 | 1974-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO741963L true NO741963L (en) | 1975-01-06 |
Family
ID=27004425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO741963A NO741963L (en) | 1973-06-11 | 1974-05-30 |
Country Status (20)
Country | Link |
---|---|
JP (1) | JPS5034095A (en) |
AR (1) | AR206115A1 (en) |
AT (1) | AT354096B (en) |
BG (1) | BG27910A3 (en) |
CA (1) | CA1075847A (en) |
CH (1) | CH614456A5 (en) |
DD (1) | DD111386A5 (en) |
DE (1) | DE2427938A1 (en) |
DK (1) | DK290174A (en) |
ES (3) | ES427097A1 (en) |
FI (1) | FI58787C (en) |
FR (1) | FR2232563B1 (en) |
GB (1) | GB1470538A (en) |
HU (1) | HU174792B (en) |
IE (1) | IE39795B1 (en) |
IL (1) | IL44957A (en) |
LU (1) | LU70277A1 (en) |
NL (1) | NL7407310A (en) |
NO (1) | NO741963L (en) |
SE (1) | SE7407017L (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4205064A (en) * | 1973-06-11 | 1980-05-27 | Merck & Co., Inc. | Bile acid sequestering composition containing poly[{alkyl-(3-ammoniopropyl)imino}-trimethylenedihalides] |
JPS53109920A (en) * | 1977-01-29 | 1978-09-26 | Kureha Chem Ind Co Ltd | Preparation of anti-tumor polysaccharides |
JPS53109915A (en) * | 1977-01-29 | 1978-09-26 | Kureha Chem Ind Co Ltd | Preparation of anti-tumor polysaccharides |
JPS53109914A (en) * | 1977-01-29 | 1978-09-26 | Kureha Chem Ind Co Ltd | Preparation of anti-tumor polysaccharides |
JPS53109918A (en) * | 1977-01-29 | 1978-09-26 | Kureha Chem Ind Co Ltd | Preparation of anti-tumor polysaccharides |
JPS53109922A (en) * | 1977-01-29 | 1978-09-26 | Kureha Chem Ind Co Ltd | Preparation of anti-tumor polysaccharides |
JPS53109919A (en) * | 1977-01-29 | 1978-09-26 | Kureha Chem Ind Co Ltd | Preparation of anti-tumor polysaccharides |
JPS53109921A (en) * | 1977-01-29 | 1978-09-26 | Kureha Chem Ind Co Ltd | Preparation of anti-tumor polysaccharides |
FI67483C (en) * | 1977-02-17 | 1985-04-10 | Merck & Co Inc | PROCEDURE FOR THE FRAMEWORK OF ETHCYCLE ADMINISTRATION OF PHARMACOLOGICAL PRODUCT AGAINST GALLSYRAK COMPLEX BILDANDE ADSORBATE PREPARATION |
US4837005A (en) * | 1986-09-30 | 1989-06-06 | Union Carbide Corporation | Partially hydrolyzed, poly(N-acyl)alkylenimines in personal care |
US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
US5496545A (en) * | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
WO1996021454A1 (en) * | 1995-01-12 | 1996-07-18 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
DE19705963A1 (en) * | 1997-02-17 | 1998-08-20 | Hoechst Ag | Crosslinked vinyl polymers with bile acid adsorber effect |
US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
US8986669B2 (en) | 2005-09-02 | 2015-03-24 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
EP3000460A1 (en) | 2005-09-15 | 2016-03-30 | Genzyme Corporation | Sachet formulation for amine polymers |
MA41202A (en) | 2014-12-18 | 2017-10-24 | Genzyme Corp | CROSS-LINKED POLYDIALLYMINE COPOLYMERS FOR THE TREATMENT OF TYPE 2 DIABETES |
-
1974
- 1974-01-01 AR AR254138A patent/AR206115A1/en active
- 1974-05-28 SE SE7407017A patent/SE7407017L/xx unknown
- 1974-05-29 DK DK290174A patent/DK290174A/da unknown
- 1974-05-30 NL NL7407310A patent/NL7407310A/xx not_active Application Discontinuation
- 1974-05-30 FI FI1661/74A patent/FI58787C/en active
- 1974-05-30 NO NO741963A patent/NO741963L/no unknown
- 1974-06-03 IL IL44957A patent/IL44957A/en unknown
- 1974-06-03 GB GB2448674A patent/GB1470538A/en not_active Expired
- 1974-06-05 CA CA201,754A patent/CA1075847A/en not_active Expired
- 1974-06-06 IE IE1188/74A patent/IE39795B1/en unknown
- 1974-06-07 ES ES427097A patent/ES427097A1/en not_active Expired
- 1974-06-07 DD DD179015A patent/DD111386A5/xx unknown
- 1974-06-07 FR FR7419711A patent/FR2232563B1/fr not_active Expired
- 1974-06-07 HU HU74ME1742A patent/HU174792B/en unknown
- 1974-06-07 AT AT472974A patent/AT354096B/en not_active IP Right Cessation
- 1974-06-10 CH CH789174A patent/CH614456A5/en not_active IP Right Cessation
- 1974-06-10 BG BG026912A patent/BG27910A3/en unknown
- 1974-06-10 LU LU70277A patent/LU70277A1/xx unknown
- 1974-06-10 DE DE19742427938 patent/DE2427938A1/en not_active Withdrawn
- 1974-06-11 JP JP49065663A patent/JPS5034095A/ja active Pending
-
1976
- 1976-05-17 ES ES448118A patent/ES448118A1/en not_active Expired
- 1976-05-21 ES ES448117A patent/ES448117A1/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
CA1075847A (en) | 1980-04-15 |
CH614456A5 (en) | 1979-11-30 |
IL44957A (en) | 1977-05-31 |
IE39795L (en) | 1974-12-11 |
FI58787C (en) | 1981-04-10 |
FI166174A (en) | 1974-12-12 |
LU70277A1 (en) | 1975-03-06 |
SE7407017L (en) | 1974-12-12 |
IL44957A0 (en) | 1974-09-10 |
ES448117A1 (en) | 1977-11-01 |
NL7407310A (en) | 1974-12-13 |
JPS5034095A (en) | 1975-04-02 |
DK290174A (en) | 1975-02-03 |
FR2232563B1 (en) | 1979-06-15 |
IE39795B1 (en) | 1979-01-03 |
FI58787B (en) | 1980-12-31 |
DD111386A5 (en) | 1975-02-12 |
ES427097A1 (en) | 1976-09-01 |
ATA472974A (en) | 1979-05-15 |
HU174792B (en) | 1980-03-28 |
AR206115A1 (en) | 1976-06-30 |
ES448118A1 (en) | 1977-11-01 |
AU6976274A (en) | 1975-12-04 |
FR2232563A1 (en) | 1975-01-03 |
DE2427938A1 (en) | 1975-01-02 |
BG27910A3 (en) | 1980-01-15 |
AT354096B (en) | 1979-12-27 |
GB1470538A (en) | 1977-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO741963L (en) | ||
US4098726A (en) | Poly[{alkyl-(3-ammoniopropyl)iminio}trimethylene dihalides] and process | |
US4205064A (en) | Bile acid sequestering composition containing poly[{alkyl-(3-ammoniopropyl)imino}-trimethylenedihalides] | |
AU672824B2 (en) | Crosslinked polymeric ammonium salts | |
US4027009A (en) | Compositions and methods for depressing blood serum cholesterol | |
US4217429A (en) | Poly-[(methylimino)trimethylene] | |
AU724507B2 (en) | Poly(diallylamine)-based bile acid sequestrants | |
US5925379A (en) | Interpenetrating polymer networks for sequestration of bile acids | |
CA2056862A1 (en) | Nitrogen derivatives | |
US4206295A (en) | Process of preparing poly[{alkyl-(3-ammoniopropyl)iminio}trimethylene dihalides] | |
US5556619A (en) | Crosslinked polymeric ammonium salts | |
US4161581A (en) | Poly-[(dialkyl and hydroxy-dialkyl-imino)ethylene halides] and process | |
US5516758A (en) | Polyamides bearing functionalized side chains useful as water soluble hypolipidemic agents | |
GB2036048A (en) | Polymer compounds, process for their preparation and arteriosclerosis treating agents containing them | |
US5874522A (en) | Crosslinked polymeric ammonium salts | |
EP0389079B1 (en) | Polyamides bearing functionalized side chains useful as water soluble hypolipidemic agents | |
KR800001617B1 (en) | The manufacturing method of ionene polymers | |
CA1087632A (en) | 3-[n'-(3-halopropyl)-n'-methylamino]-n,n,n- trimethyl-1-propanaminium halide and novel polymers | |
PL106910B1 (en) | METHOD OF MANUFACTURE OF LINEAR, INDEPENDENT, UNCINKED IONEN POLYMERS | |
KR790001445B1 (en) | 3- n -(3-haloproply)-n-methylamino -n,n,n,-trimethyl-1-propanaminium halide and acid additon salts thereof | |
US2598103A (en) | Riboflavin-glyoxal condensation products | |
MXPA99006152A (en) | Poly(diallylamine)based bile acid sequestrants |